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Abstract 
 
Kellie Rae Machlus: Pathophysiology of Plasma Hypercoagulability in Thrombosis 
(Under the direction of Dr. Alisa S. Wolberg) 
 
 Blood coagulation abnormalities are the leading cause of death world-wide.  Elevated 
procoagulant factor levels (hypercoagulability) have been correlated with increased thrombin 
generation and increased risk of arterial and venous thrombosis.  This dissertation explores 
the role of hypercoagulability on various aspects of coagulation and thrombosis in vitro and 
in vivo. 
 Thrombin generation tests are increasingly being employed as a high throughput, global 
measure of procoagulant activity.  Thrombin generation was measured using calibrated 
automated thrombography (CAT) in platelet-free plasma (PFP) and platelet-rich plasma 
(PRP).  The relative sensitivity of CAT parameters to elevated factors XI, IX, VIII, X, and 
prothrombin was:  PFP initiated with 1 pM tissue factor (TF) > PFP initiated with 5 pM TF > 
PRP initiated with 1 pM TF.  Monitoring the peak height following initiation with 1 pM TF 
in PFP was most likely to detect hypercoagulability (increased procoagulant factors). 
 Epidemiologic studies have correlated elevated plasma fibrinogen (hyperfibrinogenemia) 
with risk of arterial and venous thrombosis.  However, it is unknown whether 
hyperfibrinogenemia is a biomarker of disease or causative in the etiology.  In mice, 
hyperfibrinogenemia significantly shortened the time to occlusion (TTO) after FeCl3 injury 
to the saphenous vein and carotid artery.  Hyperfibrinogenemia increased thrombus fibrin 
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content, promoted faster fibrin formation, and increased fibrin network density, strength, and 
stability and increased thrombus thrombolysis resistance in vivo.  These data indicate 
hyperfibrinogenemia directly promotes thrombosis and thrombolysis resistance via enhanced 
fibrin formation and stability.   
Studies have correlated elevated plasma factor VIII (FVIII) with thrombosis.  However, 
like hyperfibrinogenemia, it is unclear whether elevated FVIII is a biomarker or causative 
agent.  In mice, elevated FVIII had no effect on 3-minute FeCl3 carotid artery injury, but 
shortened the TTO after 2-minute injury.  Additionally, elevated FVIII increased circulating 
thrombin-antithrombin complexes and stabilized clots after 2- but not 3-minute FeCl3 injury.  
In vitro, elevated FVIII increased thrombin generation and accelerated platelet aggregation 
only when initiated by low TF.  These results demonstrate dependence of FVIII 
thrombogenicity on extent of vascular injury.   
 These findings provide a better understanding of how plasma hypercoagulability impacts 
thrombogenesis.  Specifically, these data suggest causative yet differential roles for 
hyperfibrinogenemia and elevated FVIII in thrombosis. 
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Introduction: Procoagulant Activity in Hemostasis and Thrombosis. Virchow’s Triad 
Revisited 
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1.1  Abstract 
 Virchow’s triad is traditionally invoked to explain pathophysiologic mechanisms leading 
to thrombosis, alleging concerted roles for abnormalities in blood composition, vessel wall 
components, and blood flow/shear in the development of arterial and venous thrombosis.  
Given the tissue-specific bleeding observed in hemophilia, it may be instructive to consider 
the principles of Virchow’s Triad when interrogating mechanisms operant in hemostatic 
disorders, as well.  Blood composition (procoagulant activity of circulating blood cells and 
plasma proteins) is the most well-studied component of the triad.  For example, increased 
levels of plasma proteins such as prothrombin and fibrinogen are associated with thrombosis, 
and deficiencies in plasma factors VIII and IX result in bleeding (Hemophilia A and B, 
respectively).  Second, vessel wall components contribute both cellular adhesion molecules 
that aid in recruiting circulating leukocytes and platelets to sites of vascular damage, and 
cellular tissue factor, which provides a procoagulant signal of vascular breach and a surface 
upon which to assemble procoagulant complexes.  Third, although contributions of blood 
flow/shear to clotting are perhaps the least understood aspect of Virchow’s Triad, it appears 
the shear rate affects several aspects of coagulation, including platelet activation/deposition 
and the kinetics of fibrin monomer formation and polymerization.  Shear also affects vessel 
wall function by modulating endothelial cell procoagulant activity.  That no one abnormality 
in any component of Virchow’s Triad predicts coagulopathy a priori suggests coagulopathies 
are multifactorial in origin.  This review focuses on the procoagulant contributions of blood, 
vasculature, and flow/shear to hemostasis and thrombosis and suggests interplay between the 
three components of Virchow’s triad establishes hemostasis and determines propensity for 
thrombosis or bleeding.  Understanding these relationships is essential for effectively 
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diagnosing and treating thrombotic and bleeding disorders. 
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1.2  Introduction 
 Abnormalities in blood coagulation are the leading cause of death world-wide, with 
treatment costs estimated at over $250 billion and projected to more than triple to $818.1 
billion by 2030.[1]  In addition to inherited bleeding and thrombotic disorders, therapeutic 
approaches to manage hemostatic and thrombotic episodes are expected to paradoxically 
increase the incidence of thrombotic and bleeding events, respectively.  For example, while 
the hemostatic agent recombinant factor VIIa is highly effective at minimizing bleeding in 
hemophilic patients with inhibitors, its off-label use in non-hemophilic patients is associated 
with arterial thromboembolism.[2]  Similarly, whereas the recently approved antithrombotic 
Dabigatran exhibits improved safety and efficacy compared to Coumadin, there is no known 
antidote or reversal agent, which may leave patients prone to bleeds.[3]  Understanding 
mechanism(s) of blood coagulation and its associated disorders will allow us to design more 
targeted, effective and safe therapeutics to treat both bleeding and thrombosis. 
 
1.3  Tissue factor (TF), thrombin, and fibrin(ogen) in clot formation and stability 
 Procoagulant activities have been traditionally separated into the extrinsic, intrinsic, and 
common pathways; however, the requirement to localize thrombin generation to a site of 
injury and complex presentation of certain factor deficiencies has led to the integration of 
these pathways.[4]  Briefly, coagulation is initiated via extrinsic activity following exposure 
of cell-derived TF, formation of the factor VIIa/TF complex, and conversion of factor X to 
factor Xa.  Thrombin generation is subsequently augmented by intrinsic (factors XI, IX, and 
VIII-dependent) activities.  Though both the factor VIIa/TF and intrinsic tenase (factors 
IXa/VIIIa) complexes produce factor Xa, the relative contributions of these activities are 
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dictated, in part, by the local TF concentration and cell surface supporting enzyme/cofactor 
complex assembly (discussed below).  Cellular and plasma-dependent mechanisms culminate 
in prothrombinase complex (factors Xa, Va, and prothrombin) assembly, and production of 
the enzyme thrombin.  Most current antithrombotic agents target one or more of the active 
enzymes generated during the clotting cascade, including factors Xa, IXa, and thrombin. 
 Proteolytic conversion of circulating, soluble fibrinogen to an insoluble fibrin meshwork 
involves cleavage of N-terminal peptides from the fibrinogen substrate, subsequent end-to-
end polymerization of fibrin monomers to protofibrils, and lateral aggregation of protofibrils 
to fibers.  This sequence of events has been extensively studied and reviewed.[5-7]  Fibrin’s 
remarkable biophysical characteristics make it extraordinarily suited to provide structural 
support to the clot; individual fibers can be strained greater than 330% without rupturing.[8]  
As such, fibrin is an effective therapeutic target for both minimizing bleeding in hemostatic 
disorders[9], and dissolving intravascular thrombi in myocardial infarction, ischemic stroke, 
and deep vein thrombosis.[10-12] 
 Determinants of fibrin network characteristics have been almost entirely studied in 
purified systems or in platelet-poor plasma.  These studies have shown the conditions under 
which fibrinogen is converted to fibrin determine the fiber thickness, branching, and network 
density of the resulting clot.  These conditions include the local pH, ionic strength, and 
concentrations of calcium, polyphosphate, fibrin(ogen)-binding proteins, thrombin, and 
fibrinogen present during fibrin formation.[13-18]  Of these, the influences of the thrombin 
and fibrinogen concentrations on fibrin structure have been best characterized.  At a constant 
fibrinogen concentration, low thrombin concentrations produce coarse, unbranched networks 
of thick fibrin fibers, whereas high thrombin concentrations produce dense, highly-branched 
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networks of thin fibers [16, 17]  Similarly, at a constant thrombin concentration, increasing 
the fibrinogen concentration produces denser, highly-branched fibrin networks.[14, 17, 18]  
The structural composition of a fibrin clot is important because the structure determines its 
biochemical and mechanical properties (reviewed in [19]).  In general, coarse networks have 
a lower elastic modulus and increased susceptibility to fibrinolysis, whereas dense networks 
have a higher elastic modulus and are relatively resistant to fibrinolysis.[18, 20, 21]  
 
1.4  Pathophysiologic mechanisms in thrombosis and bleeding 
 Abnormal levels of pro- and anti-coagulant proteins[22-40], thrombin generation[34-38, 
40, 41], clotting factor activity[42], resistance to inactivation[43, 44], markers of vascular 
cell damage or activation[45, 46], and fibrinolysis inhibitors[47, 48] have each been 
correlated with thrombosis or bleeding.  That no one of these abnormalities predicts 
coagulopathy a priori suggests coagulopathies are multifactorial in origin.  Traditionally 
invoked to explain pathophysiologic mechanisms leading to thrombosis/thromboembolism, 
Virchow’s Triad postulates concerted roles for these abnormalities in blood composition, 
vessel wall components, and blood flow/shear in promoting development of arterial and 
venous thrombosis (Figure 1.1).[49] 
 Arterial thrombosis is typically associated with atherosclerotic plaque rupture, 
release/exposure of subendothelial cells and procoagulant material (TF, collagen) from 
within the plaque, activation and aggregation of platelets, and fibrin deposition, which 
produces an occlusive platelet-rich intravascular thrombus (“white clot”, Figure 1.2).  In 
contrast, venous thrombosis/thromboembolism is typically associated with plasma 
hypercoagulability and thought to be triggered by expression of procoagulant activity on  
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Figure 1.1  Virchow’s Triad suggests interplay between abnormalities in blood components, 
the vasculature, and blood flow contribute to the development of both arterial and venous 
thrombosis.  Abbreviations:  IX, factor IX; VIII, factor VIII; II, prothrombin; Fgn, 
fibrinogen; TM, thrombomodulin 
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Figure 1.2  Arterial thrombosis involves the formation of platelet-rich ‘white clots’ that form 
following rupture of atherosclerotic plaques and exposure of procoagulant material such as 
collagen and tissue factor and/or endothelial breach, in a high shear environment.  
Abbreviations:  TM, thrombomodulin; II, prothrombin; IIa, thrombin; Fgn, fibrinogen; TF, 
tissue factor 
  9 
intact endothelium from inflammation or stasis resulting from prolonged immobility.  
Venous clots are called “red clots,” with regions showing substantial erythrocyte 
incorporation (Figure 1.3).  Given the tissue-specific bleeding (predominantly joints and 
muscles) observed in humans and mice with hemophilia[50-52], it may be instructive to 
consider the principles of Virchow’s Triad when interrogating mechanisms operant in 
hemostatic disorders, as well.  In these patients, bleeding results from transection of the full 
thickness of the vessel wall and extravasation of blood into the extravascular space.  
Hemophiliacs rarely bleed into tissues with high subendothelial/extravascular TF expression, 
suggesting relative contributions from blood composition and tissue-specific procoagulant 
activity dictate hemostatic potential at an injury site.   
 Predicting thrombotic or hemorrhagic events and devising targeted approaches for 
minimizing these events requires thorough consideration of mechanisms that are common 
and unique to each of these pathologies.  This dissertation chapter focuses on the 
procoagulant contributions of blood, vasculature, and flow/shear to hemostasis and 
thrombosis. 
 
1.5  Role of plasma procoagulant activity in thrombosis and bleeding.   
 Likely due to the ease of obtaining blood for ex vivo experiments, blood composition 
(circulating blood cells and plasma proteins) is the best-characterized facet of Virchow’s 
Triad.  Techniques to evaluate the isolated effects of abnormal plasma clotting factor levels 
in purified assays have given way to technologies that measure the global hemostatic 
potential of blood and plasma.  These newer techniques permit translation of changes in 
individual factor levels to net changes in the resulting pattern of thrombin generation.   
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Figure 1.3  Venous thrombosis involves the formation of fibrin-rich “red clots” that result 
from exposure of procoagulant activity on intact endothelium plus plasma 
hypercoagulability, in a low shear environment.  Venous thrombi are thought to initiate 
behind valve pockets, where turbulent blood flow differently regulates endothelial cell 
phenotype.  Abbreviations:  TM, thrombomodulin; EPCR, endothelial protein C receptor; II, 
prothrombin; IIa, thrombin; TF, tissue factor; Fgn, fibrinogen 
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 Deficiencies in either factor VIII or IX (hemophilia A or B, respectively) are well-
characterized hypocoagulabilities in which patients produce a primary platelet plug in 
response to vascular injury, but typically re-bleed hours to days following injury.  In vitro 
studies show hemophilic plasmas exhibit reduced thrombin generation, with a prolonged 
onset and lower generation rate and peak thrombin level.[34, 35, 37, 40]  This abnormal 
thrombin generation pattern causes deficiencies in fibrin production, fibrin network density 
and permeability, and susceptibility of the fibrin network to fibrinolysis.[31, 34, 37, 38, 40, 
53-55]  Both replacement and bypassing strategies used to treat and prevent bleeding in 
hemophilia improve thrombin generation parameters and accelerate and stabilize the 
resulting fibrin clot.[34, 38, 54, 56] 
 The role(s) of elevated plasma factor levels (hypercoagulabilities) on clotting are less 
well understood.  Elevated prothrombin levels, typically associated with the G20210A 
mutation, increase risk of venous thrombosis.[22]  Hyperprothrombinemia increases the rate 
and peak of thrombin generation in vitro with reconstituted systems and patient plasmas.[57-
61]  The high thrombin generation rates promote formation of fibrin clots composed of a fine 
network of thin fibrin fibers[59] and increased activation of TAFI[62].  Although still to be 
demonstrated in vivo, these data suggest a direct connection between elevated prothrombin, 
thrombin generation, and clot stability.   
 Abnormalities in fibrin(ogen) formation and function are implicated in both bleeding and 
thrombotic disorders.  To date, over 500 fibrinogen gene mutations have been identified, 
resulting in expression of low (afibrinogenemia) or abnormally-functioning 
(dysfibrinogenemia) fibrinogen chains.  In addition, post-translational modification (e.g. 
oxidation, nitration, homocysteinylation, and glycation) of circulating fibrinogen has been 
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implicated as an “acquired dysfibrinogenemia” in prothrombotic disorders, including acute 
coronary syndrome, diabetes, hyperhomocysteinaemia, and thrombosis associated with acute 
cigarette smoke exposure, presumably because it alters fibrinogen cleavage, incorporation of 
fibrin into the fibrin network, and/or fibrin network stability (reviewed in [63]).  
Hyperfibrinogenemia is a well-established risk factor for both arterial and venous 
thrombosis[25-30, 39], however its etiologic role has been controversial.  Transgenic mice 
that over-express murine fibrinogen show elevated fibrin degradation products (D-dimer) and 
spontaneous fibrin deposition in the spleen, but only marginal shortening of the time to 75% 
occlusion following 20% ferric chloride (FeCl3) application to the carotid artery.[64-66]  
Using a different hyperfibrinogenemia model in which wild type mice were infused with 
human fibrinogen, we showed that hyperfibrinogenemia shortens the time to occlusion 
following application of 10% and 5% FeCl3 to the carotid artery and saphenous vein, 
respectively.[18]  Furthermore, hyperfibrinogenemia increases thrombus fibrin content, 
promotes faster fibrin formation, and increases fibrin network density, strength, and 
stability.[18]  Importantly, hyperfibrinogenemia increases resistance to pharmacologically-
induced thrombolysis in vivo, demonstrating a direct, etiologic link between 
hyperfibrinogenemia, thrombosis, and thrombolysis in acute settings.[18]  
 
1.6  Role of cellular procoagulant activity in thrombosis and bleeding.   
 Vascular cells contribute at least two essential functions during coagulation.  First, 
cellular adhesion molecules including P-selectin glycoprotein ligand-1 (PSGL-1) exposed 
during vascular injury recruit circulating leukocytes and platelets to sites of vascular 
damage.(Reviewed in [67])  Second, accumulation of these cells, as well as exposure of 
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active cellular TF (normally sequestered from blood in healthy humans) provides a 
procoagulant signal of vascular breach and a surface upon which to assemble procoagulant 
complexes.  Recent evidence suggests extravascular TF exists in complex with factor 
VII[68], such that vascular injury exposes the fully-formed factor VIIa/TF complex, enabling 
immediate activation of factor X to factor Xa.  Subsequent assembly of the prothrombinase 
complex (factors Xa, Va, and prothrombin) takes place on the negatively-charged lipid 
(phosphatidylserine) surface provided by TF-bearing cells and activated platelets.  Cells also 
provide a site for factor XI(a) binding and activation of factor IX, as well as assembly of the 
intrinsic tenase complex (factors IXa, VIIIa, and X) to augment thrombin generation. 
 We and others have directly compared the ability of intravascular and extravascular cells 
to support procoagulant activity.  Whereas quiescent intravascular cells have little to no TF 
activity, extravascular cells (e.g., fibroblasts and smooth muscle cells) express TF and are 
primed to trigger coagulation upon contact with blood.  Since procoagulant activity 
(thrombin generation) dictates fibrin network formation and network properties, the highly 
procoagulant extravascular cells support the rapid production of a dense fibrin network that is 
relatively resistant to fibrinolysis.[69-71]  Such networks stabilize the primary platelet plug 
at a site of vascular injury.  The ability of extravascular procoagulant activity to trigger 
clotting in blood escaping from a vessel can be implicated in tissue-specific hemostasis.  
Vascular breach into a site of high TF activity would not require an intact intrinsic pathway; 
thrombin generation could take place entirely via the TF-driven extrinsic pathway.  In 
contrast, vessel disruption into tissues with lower extravascular TF expression would 
necessitate intrinsic pathway activity to augment thrombin generation and promote stable 
fibrin formation.  Indeed, hemophilia patients frequently bleed into muscles and joints, which 
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has been related to physical stress placed on these tissues.[50-52]  However, hemophilia 
patients do not bleed into other tissues that endure high physical activity such as the heart, 
suggesting that attributing bleeding solely to physical stress oversimplifies the pathology.  
Cardiomyocytes express high levels of TF, which can promote substantial thrombin 
generation independently of intrinsic factors VIII and IX, suggesting tissue-specific extrinsic 
activity can compensate for reduced intrinsic activity.  This scenario illustrates the required 
integration of two components of Virchow’s Triad – blood and tissues – in maintaining 
hemostasis. 
 Extravascular TF expression is implicated in arterial thrombosis resulting from 
atherosclerotic plaque rupture.  The amount of TF found in atherosclerotic plaques in humans 
is positively correlated with the thrombogenicity of the lesions after plaque rupture.[72]  The 
importance of TF in the progression of arterial thrombosis is underscored by observations 
that treatment of human plaques with TFPI significantly reduces adhesion of both fibrinogen 
and platelets to the plaque, indicating the thrombotic potential of atherosclerotic lesions may 
be decreased by inhibiting TF-dependent procoagulant activity.[73]  
 Inappropriate expression of intravascular procoagulant activity is hypothesized to trigger 
venous thromboembolism.  Pro-inflammatory mediators including bacterial 
lipopolysaccharide, and the cytokines interleukin-1β and tumor necrosis factor-α (TNFα), 
induce procoagulant activity in cultured endothelial cells via de novo TF synthesis and 
decreased thrombomodulin expression in a time- and dose-dependent manner.[18, 70, 74, 75] 
TNFα-stimulated endothelial cells support robust fibrin formation.[18, 70]  Laser-induced 
injury of cultured endothelial cells has also been shown to induce procoagulant activity and 
fibrin formation, although the time course of those experiments suggests TF activity is 
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released from intracellular stores and is not synthesized de novo.[76]  In vivo, endothelial 
cells residing in different vascular beds (e.g., aorta versus pulmonary microcirculation) have 
different phenotypes.  Even within a given vessel, endothelial cells vary in their expression of 
coagulation proteins.  Brooks et al. elegantly showed increased expression of 
thrombomodulin and endothelial cell protein C receptor, and decreased expression of von 
Willebrand factor in the valve sinus relative to the immediately adjacent vein lumen in the 
saphenous vein harvested during cardiac bypass surgery.[77]  Although these studies 
convincingly show vascular bed-specific expression of anticoagulant proteins on endothelial 
cells, evidence for endothelial cell TF expression in vivo remains controversial. 
 Vascular bed-specific function is best illustrated clinically by the specific presentations of 
thrombosis in either arterial or venous circulation, but rarely both.  For example, risk factors 
strongly associated with arterial thrombosis only modestly increase risk of venous 
thrombosis/thromboembolism; compared with control subjects, the risk of VTE is 1.51 for 
hypertension, 1.42 for diabetes mellitus, 1.18 for smoking and 1.16 for 
hypercholesterolemia.[78]  In addition, meta-analysis suggests history of unprovoked venous 
thrombosis only slightly increases (~1.5-fold) risk of arterial cardiovascular events over long-
term followup.[79]  Since any abnormality in the blood is present systemically, these events 
reflect contributions from unique vascular bed-specific pro- or anti-coagulant activity and/or 
shear rates (discussed below).  Vascular bed-specific activities are illustrated by animal 
models of coagulation dysfunction showing bleeding and/or fibrin deposition in specific 
tissues.  For example, mice with partial TFPI deficiency and decreased TM function 
demonstrate fibrin deposition in the brain and liver, but not other tissues.[80]  These 
observations suggest critical functions of anticoagulant proteins in specific tissues. 
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 Neither “cell” nor “plasma protein,” cell-derived microparticles express cell-specific 
markers and retain procoagulant properties derived from their parent cell, and can circulate 
and evade normal cell regulatory mechanisms.  Although circulating microparticles derived 
from leukocytes, platelets, erythrocytes, endothelium, megakayocytes, and tumors have been 
identified in numerous studies (Figure 1.4), their precise role(s) in hemostasis and thrombosis 
is poorly understood.  Scott’s syndrome patients with a defect in membrane regulation that 
reduces the number of circulating platelet-derived microparticles exhibit a bleeding 
defect[81]; however, it is difficult to separate the role(s) of reduced expression of 
phosphatidylserine on platelets and reduced production of phosphatidylserine-bearing 
microparticles.  Healthy humans have few circulating leukocyte-derived microparticles; 
however, the numbers of leukocyte-derived microparticles rise in certain diseases, including 
cancer[82, 83], diabetes[84], and sickle cell disease[85].  Microparticles derived directly 
from tumors have also been specifically associated with venous thromboembolism in cancer 
patients, and are thought to contribute to the thrombotic presentation.[86, 87]  Expression of 
procoagulant activity on microparticles (TF and/or phosphatidylserine) has been implicated 
in microparticle function in vitro and in vivo.  One prospective study demonstrated a sharp 
rise in microparticle TF activity immediately prior to venous thrombosis in two patients[83], 
suggesting a causative role of microparticles in the thrombotic event.  Murine studies support 
this observation; human monocyte-derived microparticles promote thrombus formation[88, 
89] and increase thrombus weight[90] in intravascular thrombosis models.   Additional 
theories regarding the mechanistic role(s) of microparticles in thrombosis invoke their 
expression of cellular adhesion molecules (from their parent cell), and ability to activate  
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endothelium and leukocytes. 
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Figure 1.4  Circulating microparticles are derived from a variety of cell types including 
leukocytes, platelets, megakaryocytes, red blood cells, endothelial cells, and tumors.  
Microparticles carry cell-specific markers and functional properties of their parent cell. 
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 1.7  Role of flow/shear in thrombosis and bleeding.   
 The contributions of blood flow/shear to clotting are perhaps the least interrogated aspect 
of Virchow’s Triad.  Biological models for examining platelets and endothelial cells in their 
native shear environments are technically challenging; reconstituting a sufficient model of 
the vasculature in fluidics devices to visualize clot formation has been difficult.  Most 
frequently studied is the role of shear in platelet deposition at sites of vascular damage.  
Typical venous and arterial shear rates are 10-100 s-1 and 500-1500 s-1, respectively, although 
shear may reach 70,000 s-1 to 250,000 s-1 in severely stenotic vessels.[91, 92]  Platelet 
deposition rates increase with shear rates in a vWF-dependent mechanism.[93, 94]  Shear-
dependent expression of platelet P-selectin and formation of monocyte-platelet aggregates 
suggest that both platelets and leukocytes are activated when they traverse stenotic regions, 
priming these cells for deposition on dysfunctioning or ruptured vasculature.[95]  Moreover, 
soluble agonist-independent accumulation of platelets at a stenotic region is attributed to flow 
(rheology)-dependent aggregation.[96]  Both systemic and pulmonary hypertension increases 
shear stress and mechanical damage to arteries, increasing circulating levels of both 
endothelial- and platelet-derived microparticles.[97]  Accumulation of platelets and 
procoagulant microparticles is expected to not only increase thrombus mass and decrease 
lumen size at a developing thrombus (further increasing the local shear rate), but also provide 
additional surface for thrombin generation and subsequent fibrin deposition, further 
stabilizing the growing thrombus.   
 Stasis induced by immobility (hospitalization or long-haul air travel) also alters local 
shear rates, which can subsequently modulate the endothelial cell phenotype.  The flow-
responsive Kruppel-like transcription factors (KLF) have been implicated in shear-dependent 
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endothelial cell function.[98-100]  In general, laminar shear stress upregulates KLF 
expression, inducing expression of anti-inflammatory and antithrombotic proteins, including 
thrombomodulin; whereas, stasis- or proinflammatory cytokine-induced loss of KLF 
expression leads to enhanced expression of vascular cell adhesion molecule-1 and TF.[101, 
102]  As such, KLF regulation represents an intriguing therapeutic approach for novel 
antithrombotics aimed at combating stasis-induced thrombosis. 
 Interestingly, flow/shear also dramatically modulates the kinetics of both fibrin monomer 
formation and polymerization.[103, 104]  At a constant shear rate, initiation of clotting is a 
function of the size of the exposed region of TF.[103]  Once initiated, shear dictates both 
influx of procoagulant reactants including prothrombin and fibrinogen, and efflux of reaction 
products including thrombin and fibrin.  In in vitro assays, increasing shear from 10 to 100 s-1 
depletes local fibrin monomer concentrations, limiting lateral aggregation and protofibril 
extension.  However, increasing thrombin generation or decreasing shear increases local 
monomer concentrations, permitting protofibril and subsequent fibrin fiber formation.[104]  
Although fibrin networks formed under static conditions show an isotropic distribution of 
fibers with relatively uniform diameters, fibrin produced in flowing blood is oriented along 
flow vectors[104-106], with a prominent network of thick fibers as well as fiber “aggregates” 
in which multiple individual fibers are coalesced into bundles.[106]  Since the fibrin 
network’s ability to withstand both biochemical dissolution and mechanical disruption is a 
function of its fiber thickness and branching[19], these studies indicate networks produced 
under flow would demonstrate significantly different stability than isotropic networks formed 
under stasis.[106].  In fact, a recent study found that mechanical stress creates fibrin 
networks that are resistant to fibrinolysis[107], underscoring the importance of the effects of 
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flow/shear on thrombus formation, structure and function. 
 
1.8  Multiple “hits” in thrombosis and bleeding 
 Virchow’s proposition that multiple “hits” culminate in abnormal coagulation suggests 
simultaneous consideration of soluble, cellular, and physical biomarkers is required to 
delineate the pathophysiology of these disorders.  For example, the prognostic importance of 
hyperfibrinogenemia appears to be independent of, but additive to, myocardial damage 
(assessed by troponin-T levels) in patients with unstable coronary artery disease.[30]  
However, few diagnostic algorithms simultaneously consider markers of vascular damage 
and plasma hypercoagulability when determining thrombosis risk.  Acevedo et al.[27] 
showed that elevated levels of both homocysteine (a trigger of endothelial damage) and 
fibrinogen contributed to an increased hazard ratio in patients in a high-risk thrombosis 
cardiology clinic.  These studies suggest dysfunction in components of the blood and vessel 
wall simultaneously create an environment conducive to thrombosis.   
 
1.9  Conclusions 
 Understanding the interplay between the components of Virchow’s triad is necessary to 
effectively diagnose and treat bleeding and thrombotic disorders.  Increasing awareness of 
the complexities of these presentations, along with increasingly sophisticated technologies to 
analyze soluble, cellular, and physical dysfunctions in concert will shed new light on these 
pathologies and identify novel therapeutic targets.  With such targets, we can achieve the 
long-sought grail for coagulation disorders: antithrombotics with no bleeding risk and 
hemostatic agents with no thrombotic risk. 
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1.10  Focus of this dissertation 
 There remains much to learn about the three arms of Virchow’s triad and their separate 
and combined role(s) in both bleeding and thrombotic disorders.  However, this dissertation 
is focused primarily on plasma hypercoagulability and thrombosis.  Specifically, this thesis 
will address 1) the effect of elevated plasma coagulation factors on thrombin generation, 2) 
the role of elevated fibrinogen (hyperfibrinogenemia) on thrombosis and thrombolysis and 3) 
the role of elevated factor VIII on thrombus formation and stability. 
  23 
1.11  References 
 
1. Heidenreich, P.A., et al., Forecasting the future of cardiovascular disease in 
the United States: a policy statement from the American Heart Association. 
Circulation, 2011. 123(8): p. 933-44. 
2. Yank, V., et al., Systematic review: benefits and harms of in-hospital use of 
recombinant factor VIIa for off-label indications. Ann Intern Med, 2011. 
154(8): p. 529-40. 
3. Schwartz, N.E. and G.W. Albers, Dabigatran challenges warfarin's 
superiority for stroke prevention in atrial fibrillation. Stroke, 2010. 41(6): p. 
1307-9. 
4. Gailani, D. and G.J. Broze, Jr., Factor XI activation in a revised model of 
blood coagulation. Science, 1991. 253(5022): p. 909-12. 
5. Weisel, J.W., Structure of fibrin: impact on clot stability. J Thromb Haemost, 
2007. 5 Suppl 1: p. 116-24. 
6. Chernysh, I.N., C. Nagaswami, and J.W. Weisel, Visualization and 
identification of the structures formed during early stages of fibrin 
polymerization. Blood, 2011. 117(17): p. 4609-14. 
7. Lord, S.T., Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin 
Hematol, 2007. 14(3): p. 236-41. 
8. Liu, W., et al., Fibrin fibers have extraordinary extensibility and elasticity. 
Science, 2006. 313(5787): p. 634. 
9. Ghosh, K., et al., Role of epsilon amino caproic acid in the management of 
haemophilic patients with inhibitors. Haemophilia, 2004. 10(1): p. 58-62. 
10. Tissue plasminogen activator for acute ischemic stroke. The National Institute 
of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J 
Med, 1995. 333(24): p. 1581-7. 
  24 
11. Popuri, R.K. and S. Vedantham, The role of thrombolysis in the clinical 
management of DVT. Arterioscler Thromb Vasc Biol, 2011. 
12. White, H.D., et al., Effect of intravenous streptokinase as compared with that 
of tissue plasminogen activator on left ventricular function after first 
myocardial infarction. N Engl J Med, 1989. 320(13): p. 817-21. 
13. Nair, C.H., G.A. Shah, and D.P. Dhall, Effect of temperature, pH and ionic 
strength and composition on fibrin network structure and its development. 
Thromb Res, 1986. 42(6): p. 809-16. 
14. Glover, C.J., et al., Rheological properties of fibrin clots. Effects of fibrinogen 
concentration, Factor XIII deficiency, and Factor XIII inhibition. J Lab Clin 
Med, 1975. 86(4): p. 644-56. 
15. Smith, S.A. and J.H. Morrissey, Polyphosphate enhances fibrin clot structure. 
Blood, 2008. 112(7): p. 2810-6. 
16. Blomback, B., et al., Fibrin in human plasma: gel architectures governed by 
rate and nature of fibrinogen activation. Thromb Res, 1994. 75(5): p. 521-38. 
17. Ryan, E.A., et al., Structural origins of fibrin clot rheology. Biophys J, 1999. 
77(5): p. 2813-26. 
18. Machlus, K.R., et al., Causal relationship between hyperfibrinogenemia, 
thrombosis, and resistance to thrombolysis in mice. Blood, 2011. 117(18): p. 
4953-63. 
19. Weisel, J.W. and R.I. Litvinov, The biochemical and physical process of 
fibrinolysis and effects of clot structure and stability on the lysis rate. 
Cardiovasc Hematol Agents Med Chem, 2008. 6(3): p. 161-80. 
20. Collet, J.P., et al., Influence of fibrin network conformation and fibrin fiber 
diameter on fibrinolysis speed: dynamic and structural approaches by 
confocal microscopy. Arterioscler Thromb Vasc Biol, 2000. 20(5): p. 1354-
61. 
  25 
21. Carr, M.E., Jr. and B.M. Alving, Effect of fibrin structure on plasmin-
mediated dissolution of plasma clots. Blood Coagul Fibrinolysis, 1995. 6(6): 
p. 567-73. 
22. Poort, S.R., et al., A common genetic variation in the 3'-untranslated region of 
the prothrombin gene is associated with elevated plasma prothrombin levels 
and an increase in venous thrombosis. Blood, 1996. 88(10): p. 3698-703. 
23. Kyrle, P.A., et al., High plasma levels of factor VIII and the risk of recurrent 
venous thromboembolism. N Engl J Med, 2000. 343(7): p. 457-62. 
24. Kamphuisen, P.W., J.C. Eikenboom, and R.M. Bertina, Elevated factor VIII 
levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol, 2001. 21(5): 
p. 731-8. 
25. Danesh, J., et al., Plasma fibrinogen level and the risk of major 
cardiovascular diseases and nonvascular mortality: an individual participant 
meta-analysis. JAMA, 2005. 294(14): p. 1799-809. 
26. Wilhelmsen, L., et al., Fibrinogen as a risk factor for stroke and myocardial 
infarction. N Engl J Med, 1984. 311(8): p. 501-5. 
27. Acevedo, M., et al., Elevated fibrinogen and homocysteine levels enhance the 
risk of mortality in patients from a high-risk preventive cardiology clinic. 
Arterioscler Thromb Vasc Biol, 2002. 22(6): p. 1042-5. 
28. Yarnell, J.W., et al., Fibrinogen, viscosity, and white blood cell count are 
major risk factors for ischemic heart disease. The Caerphilly and Speedwell 
collaborative heart disease studies. Circulation, 1991. 83(3): p. 836-44. 
29. Kannel, W.B., et al., Fibrinogen and risk of cardiovascular disease. The 
Framingham Study. JAMA, 1987. 258(9): p. 1183-6. 
30. Toss, H., et al., Prognostic influence of increased fibrinogen and C-reactive 
protein levels in unstable coronary artery disease. FRISC Study Group. 
Fragmin during Instability in Coronary Artery Disease. Circulation, 1997. 
96(12): p. 4204-10. 
  26 
31. Biggs, R., et al., Christmas disease: a condition previously mistaken for 
haemophilia. Br Med J, 1952. 2(4799): p. 1378-82. 
32. Griffin, J.H., et al., Deficiency of protein C in congenital thrombotic disease. J 
Clin Invest, 1981. 68(5): p. 1370-3. 
33. Pabinger, I. and B. Schneider, Thrombotic risk in hereditary antithrombin III, 
protein C, or protein S deficiency. A cooperative, retrospective study. 
Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on 
Natural Inhibitors. Arterioscler Thromb Vasc Biol, 1996. 16(6): p. 742-8. 
34. Wolberg, A.S., et al., High dose factor VIIa improves clot structure and 
stability in a model of haemophilia B. Br J Haematol, 2005. 131(5): p. 645-55. 
35. Dargaud, Y., et al., Evaluation of thrombin generating capacity in plasma 
from patients with haemophilia A and B. Thromb Haemost, 2005. 93(3): p. 
475-80. 
36. Al Dieri, R., et al., The thrombogram in rare inherited coagulation disorders: 
its relation to clinical bleeding. Thromb Haemost, 2002. 88(4): p. 576-82. 
37. Butenas, S., et al., Models of blood coagulation. Blood Coagul Fibrinolysis, 
2000. 11 Suppl 1: p. S9-13. 
38. Allen, G.A., et al., A variant of recombinant factor VIIa with enhanced 
procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. 
Arterioscler Thromb Vasc Biol, 2007. 27(3): p. 683-9. 
39. van Hylckama Vlieg, A. and F.R. Rosendaal, High levels of fibrinogen are 
associated with the risk of deep venous thrombosis mainly in the elderly. J 
Thromb Haemost, 2003. 1(12): p. 2677-8. 
40. Macfarlane, R.G. and R. Biggs, A thrombin generation test; the application in 
haemophilia and thrombocytopenia. J Clin Pathol, 1953. 6(1): p. 3-8. 
41. Hron, G., et al., Identification of patients at low risk for recurrent venous 
thromboembolism by measuring thrombin generation. JAMA, 2006. 296(4): 
p. 397-402. 
  27 
42. Simioni, P., et al., X-linked thrombophilia with a mutant factor IX (factor IX 
Padua). N Engl J Med, 2009. 361(17): p. 1671-5. 
43. Zoller, B., et al., Identification of the same factor V gene mutation in 47 out of 
50 thrombosis-prone families with inherited resistance to activated protein C. 
J Clin Invest, 1994. 94(6): p. 2521-4. 
44. Bertina, R.M., et al., Mutation in blood coagulation factor V associated with 
resistance to activated protein C. Nature, 1994. 369(6475): p. 64-7. 
45. Lindahl, B., et al., Markers of myocardial damage and inflammation in 
relation to long-term mortality in unstable coronary artery disease. FRISC 
Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl 
J Med, 2000. 343(16): p. 1139-47. 
46. Chirinos, J.A., et al., Elevation of endothelial microparticles, platelets, and 
leukocyte activation in patients with venous thromboembolism. J Am Coll 
Cardiol, 2005. 45(9): p. 1467-71. 
47. Meltzer, M.E., et al., Venous thrombosis risk associated with plasma 
hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. 
Blood, 2010. 116(1): p. 113-21. 
48. Fay, W.P., et al., Human plasminogen activator inhibitor-1 (PAI-1) 
deficiency: characterization of a large kindred with a null mutation in the 
PAI-1 gene. Blood, 1997. 90(1): p. 204-8. 
49. Virchow, R., Thrombose und embolie. Gefässentzündung und septische 
infektion. Gesammelte Abhandlungen zur wissenschaftlichen Medicin. 1856, 
Frankfurt: Von Meidinger & Sohn. 
50. Bolton-Maggs, P.H. and K.J. Pasi, Haemophilias A and B. Lancet, 2003. 
361(9371): p. 1801-9. 
51. Soucie, J.M., et al., Joint range-of-motion limitations among young males with 
hemophilia: prevalence and risk factors. Blood, 2004. 103(7): p. 2467-73. 
52. Roosendaal, G. and F.P. Lafeber, Blood-induced joint damage in hemophilia. 
Semin Thromb Hemost, 2003. 29(1): p. 37-42. 
  28 
53. Bettigole, R.E., J.W. Hampton, and R.M. Bird, Abnormal Plasma Clots in 
Hemophilia. Thromb Diath Haemorrh, 1964. 12: p. 331-7. 
54. He, S., et al., The role of recombinant factor VIIa (FVIIa) in fibrin structure in 
the absence of FVIII/FIX. J Thromb Haemost, 2003. 1(6): p. 1215-9. 
55. Brummel-Ziedins, K.E., et al., Discordant fibrin formation in hemophilia. J 
Thromb Haemost, 2009. 7(5): p. 825-32. 
56. Sorensen, B., E. Persson, and J. Ingerslev, Factor VIIa analogue 
(V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from 
patients with severe haemophilia A. Br J Haematol, 2007. 137(2): p. 158-65. 
57. Allen, G.A., et al., Impact of procoagulant concentration on rate, peak and 
total thrombin generation in a model system. J Thromb Haemost, 2004. 2(3): 
p. 402-13. 
58. Butenas, S., C. van't Veer, and K.G. Mann, "Normal" thrombin generation. 
Blood, 1999. 94(7): p. 2169-78. 
59. Wolberg, A.S., et al., Elevated prothrombin results in clots with an altered 
fiber structure: a possible mechanism of the increased thrombotic risk. Blood, 
2003. 101(8): p. 3008-13. 
60. Machlus, K.R., et al., Effects of tissue factor, thrombomodulin and elevated 
clotting factor levels on thrombin generation in the calibrated automated 
thrombogram. Thromb Haemost, 2009. 102(5): p. 936-44. 
61. Kyrle, P.A., et al., Clinical studies and thrombin generation in patients 
homozygous or heterozygous for the G20210A mutation in the prothrombin 
gene. Arterioscler Thromb Vasc Biol, 1998. 18(8): p. 1287-91. 
62. Colucci, M., et al., Hyperprothrombinemia associated with prothrombin 
G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated 
mechanism. Blood, 2004. 103(6): p. 2157-61. 
63. Hoffman, M., Alterations of fibrinogen structure in human disease. 
Cardiovasc Hematol Agents Med Chem, 2008. 6(3): p. 206-11. 
  29 
64. Gulledge, A.A., et al., A novel transgenic mouse model of 
hyperfibrinogenemia. Thromb Haemost, 2001. 86(2): p. 511-6. 
65. Gulledge, A.A., et al., Effects of hyperfibrinogenemia on vasculature of 
C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc 
Biol, 2003. 23(1): p. 130-5. 
66. Kerlin, B., et al., Cause-effect relation between hyperfibrinogenemia and 
vascular disease. Blood, 2004. 103(5): p. 1728-34. 
67. Vandendries, E.R., B.C. Furie, and B. Furie, Role of P-selectin and PSGL-1 in 
coagulation and thrombosis. Thromb Haemost, 2004. 92(3): p. 459-66. 
68. Hoffman, M., et al., Tissue factor around dermal vessels has bound factor VII 
in the absence of injury. J Thromb Haemost, 2007. 5(7): p. 1403-8. 
69. Campbell, R.A., et al., Cellular procoagulant activity dictates clot structure 
and stability as a function of distance from the cell surface. Arterioscler 
Thromb Vasc Biol, 2008. 28(12): p. 2247-54. 
70. Campbell, R.A., et al., Contributions of extravascular and intravascular cells 
to fibrin network formation, structure, and stability. Blood, 2009. 114(23): p. 
4886-96. 
71. Ovanesov, M.V., et al., Initiation and propagation of coagulation from tissue 
factor-bearing cell monolayers to plasma: initiator cells do not regulate 
spatial growth rate. J Thromb Haemost, 2005. 3(2): p. 321-31. 
72. Toschi, V., et al., Tissue factor modulates the thrombogenicity of human 
atherosclerotic plaques. Circulation, 1997. 95(3): p. 594-9. 
73. Badimon, J.J., et al., Local inhibition of tissue factor reduces the 
thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue 
factor pathway inhibitor on plaque thrombogenicity under flow conditions. 
Circulation, 1999. 99(14): p. 1780-7. 
74. Herbert, J.M., et al., IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced 
expression of tissue factor in endothelial cells and monocytes. FEBS Lett, 
1992. 310(1): p. 31-3. 
  30 
75. Bevilacqua, M.P., et al., Recombinant tumor necrosis factor induces 
procoagulant activity in cultured human vascular endothelium: 
characterization and comparison with the actions of interleukin 1. Proc Natl 
Acad Sci U S A, 1986. 83(12): p. 4533-7. 
76. Atkinson, B.T., et al., Laser-induced endothelial cell activation supports 
fibrin formation. Blood, 2010. 116(22): p. 4675-83. 
77. Brooks, E.G., et al., Valves of the deep venous system: an overlooked risk 
factor. Blood, 2009. 114(6): p. 1276-9. 
78. Ageno, W., et al., Cardiovascular risk factors and venous thromboembolism: 
a meta-analysis. Circulation, 2008. 117(1): p. 93-102. 
79. Becattini, C., et al., Incidence of arterial cardiovascular events after venous 
thromboembolism: a systematic review and a meta-analysis. J Thromb 
Haemost, 2010. 8(5): p. 891-7. 
80. Maroney, S.A., et al., Combined tissue factor pathway inhibitor and 
thrombomodulin deficiency produces an augmented hypercoagulable state 
with tissue-specific fibrin deposition. J Thromb Haemost, 2008. 6(1): p. 111-7. 
81. Sims, P.J., et al., Assembly of the platelet prothrombinase complex is linked to 
vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an 
isolated defect in platelet procoagulant activity. J Biol Chem, 1989. 264(29): 
p. 17049-57. 
82. Kanazawa, S., et al., Monocyte-derived microparticles may be a sign of 
vascular complication in patients with lung cancer. Lung Cancer, 2003. 39(2): 
p. 145-9. 
83. Khorana, A.A., et al., Plasma tissue factor may be predictive of venous 
thromboembolism in pancreatic cancer. J Thromb Haemost, 2008. 6(11): p. 
1983-5. 
84. Tripodi, A., et al., Hypercoagulability in patients with type 2 diabetes mellitus 
detected by a thrombin generation assay. J Thromb Thrombolysis, 2011. 
31(2): p. 165-72. 
  31 
85. Shet, A.S., et al., Sickle blood contains tissue factor-positive microparticles 
derived from endothelial cells and monocytes. Blood, 2003. 102(7): p. 2678-
83. 
86. Tesselaar, M.E., et al., Microparticle-associated tissue factor activity in 
cancer patients with and without thrombosis. J Thromb Haemost, 2009. 7(8): 
p. 1421-3. 
87. Zwicker, J.I., et al., Tumor-derived tissue factor-bearing microparticles are 
associated with venous thromboembolic events in malignancy. Clin Cancer 
Res, 2009. 15(22): p. 6830-40. 
88. Biro, E., et al., Human cell-derived microparticles promote thrombus 
formation in vivo in a tissue factor-dependent manner. J Thromb Haemost, 
2003. 1(12): p. 2561-8. 
89. Reinhardt, C., et al., Protein disulfide isomerase acts as an injury response 
signal that enhances fibrin generation via tissue factor activation. J Clin 
Invest, 2008. 118(3): p. 1110-22. 
90. Ramacciotti, E., et al., Leukocyte- and platelet-derived microparticles 
correlate with thrombus weight and tissue factor activity in an experimental 
mouse model of venous thrombosis. Thromb Haemost, 2009. 101(4): p. 748-
54. 
91. Bark, D.L., Jr. and D.N. Ku, Wall shear over high degree stenoses pertinent to 
atherothrombosis. J Biomech, 2010. 43(15): p. 2970-7. 
92. Siegel, J.M., et al., A scaling law for wall shear rate through an arterial 
stenosis. J Biomech Eng, 1994. 116(4): p. 446-51. 
93. Badimon, L., J.H. Chesebro, and J.J. Badimon, Thrombus formation on 
ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. 
Circulation, 1992. 86(6 Suppl): p. III74-85. 
94. Badimon, L., et al., Role of von Willebrand factor in mediating platelet-vessel 
wall interaction at low shear rate; the importance of perfusion conditions. 
Blood, 1989. 73(4): p. 961-7. 
  32 
95. Yong, A.S., et al., Intracoronary shear-related up-regulation of platelet P-
selectin and platelet-monocyte aggregation despite the use of aspirin and 
clopidogrel. Blood, 2011. 117(1): p. 11-20. 
96. Nesbitt, W.S., et al., A shear gradient-dependent platelet aggregation 
mechanism drives thrombus formation. Nat Med, 2009. 15(6): p. 665-73. 
97. Preston, R.A., et al., Effects of severe hypertension on endothelial and platelet 
microparticles. Hypertension, 2003. 41(2): p. 211-7. 
98. Lin, Z., et al., Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic 
function. Circ Res, 2005. 96(5): p. e48-57. 
99. Dekker, R.J., et al., KLF2 provokes a gene expression pattern that establishes 
functional quiescent differentiation of the endothelium. Blood, 2006. 107(11): 
p. 4354-63. 
100. Hamik, A., et al., Kruppel-like factor 4 regulates endothelial inflammation. J 
Biol Chem, 2007. 282(18): p. 13769-79. 
101. Bhattacharya, R., et al., Inhibition of vascular permeability factor/vascular 
endothelial growth factor-mediated angiogenesis by the Kruppel-like factor 
KLF2. J Biol Chem, 2005. 280(32): p. 28848-51. 
102. Parmar, K.M., et al., Integration of flow-dependent endothelial phenotypes by 
Kruppel-like factor 2. J Clin Invest, 2006. 116(1): p. 49-58. 
103. Shen, F., et al., Threshold Response of Initiation of Blood Coagulation by 
Tissue Factor in Patterned Microfluidic Capillaries Is Controlled by Shear 
Rate. Arterioscler Thromb Vasc Biol, 2008. 28: p. 2035-2041. 
104. Neeves, K.B., D.A. Illing, and S.L. Diamond, Thrombin flux and wall shear 
rate regulate fibrin fiber deposition state during polymerization under flow. 
Biophys J, 2010. 98(7): p. 1344-52. 
105. Wielders, S.J., et al., Absence of platelet-dependent fibrin formation in a 
patient with Scott syndrome. Thromb Haemost, 2009. 102(1): p. 76-82. 
  33 
106. Campbell, R.A., et al., Flow profoundly influences fibrin network structure: 
implications for fibrin formation and clot stability in haemostasis. Thromb 
Haemost, 2010. 104(6): p. 1281-4. 
107. Varju, I., et al., Hindered dissolution of fibrin formed under mechanical 
stress. J Thromb Haemost, 2011. 9(5): p. 979-86. 
 
 
Chapter 2 
 
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin 
generation in the calibrated automated thrombogram 
This chapter is based on and reproduced in part with permission from: 
Machlus KR, Colby EA, Wu JR, Koch GC, Key NS, Wolberg AS.  Effects of tissue 
factor, thrombomodulin, and elevated clotting factor levels on thrombin generation in the 
calibrated automated thrombogram. Thrombosis Haemostasis, 2009, 102(5):936-944 
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2.1  Abstract 
Background:  Elevated procoagulant levels have been correlated with increased thrombin 
generation in vitro and with increased venous thromboembolism (VTE) risk in 
epidemiological studies.  Thrombin generation tests are increasingly being employed as a 
high throughput method to provide a global measure of procoagulant activity in plasma 
samples.  Objectives:  Distinguish the effects of assay conditions [tissue factor (TF), 
thrombomodulin, platelets/lipids] and factor levels on thrombin generation parameters, and 
determine the conditions and parameters with the highest sensitivity and specificity for 
detecting elevated factor levels.  Methods:  Thrombin generation was measured using 
calibrated automated thrombography (CAT) in corn trypsin inhibitor (CTI)-treated platelet-
free plasma (PFP) and platelet-rich plasma (PRP).  Statistical analysis was performed using 
logarithms of observed values with analysis of variance that accounted for experiment and 
treatment.  Results:  The relative sensitivity of lag time (LT), time to peak (TTP), peak height 
and endogenous thrombin potential (ETP) to elevated factors XI, IX, VIII, X, and 
prothrombin was as follows:  PFP initiated with 1 pM TF > PFP initiated with 5 pM TF > 
PRP initiated with 1 pM TF.  For all conditions, inclusion of thrombomodulin prolonged the 
LT and decreased the peak and ETP; however, addition of thrombomodulin did not increase 
the ability of CAT to detect elevated levels of individual procoagulant factors.  Conclusions:  
CAT conditions differentially affected the sensitivity of thrombin generation to elevated 
factor levels.  Monitoring the peak height and/or ETP following initiation of clotting in PFP 
with 1 pM TF was most likely to detect hypercoagulability due to increased procoagulant 
factor levels. 
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2.2  Introduction 
 Thrombin activates platelets, converts fibrinogen to fibrin, and initiates wound healing.  
Elevated procoagulant levels are correlated with abnormal thrombin generation in vitro[1-5] 
and increased risk of VTE.[6-12]  For example, prothrombin concentrations >115% of 
normal are associated with a 2.1-fold increased VTE risk, and factor VIII concentrations 
>200% are associated with markedly elevated VTE risk (OR=10.8).[6, 7]  Tests that assess 
the ability of plasma to generate thrombin are thought to provide a more global measure of 
hemostasis and thrombosis than standard clotting assays.  Such tests may be useful for 
determining risk of primary and recurrent VTE, and therefore, duration of antithrombotic 
therapy. 
 The most commonly used assay for continuous thrombin measurement is calibrated 
automated thrombography (CAT).[13]  CAT is based on monitoring cleavage of a slow-
reacting fluorogenic substrate and comparing it to a known thrombin concentration added to 
non-clotting samples.[13]  Studies have demonstrated CAT’s ability to detect reduced 
thrombin generation in clotting factor deficiency.[14-17]  CAT appears most sensitive to 
hypocoagulability when initiated by low (1 pM) TF.[16]   
Given these findings, it is logical to hypothesize that CAT can be used to detect 
hypercoagulability due to elevated factor levels.  Using high (184–429 pM) TF and no added 
phospholipids, Siegemund et al. observed increased ETP in platelet-poor plasma with high 
concentrations of factors XI and IX, but not VIII.[4]  In contrast, in PRP assays in which 
clotting was initiated with low (0.5 pM) TF, Regnault et al. observed increased ETP with 
elevated factor VIII.[3]  Several studies have correlated recurrent VTE risk with elevated 
peak height and/or ETP.[18-24]  However, another study correlated abnormal thrombin 
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generation with first, but not recurrent VTE.[25]  It has been proposed that differences in 
findings from these studies stem, in part, from variations in assay conditions.[25-27]  
Notably, these studies differed in the source and concentration of TF and phospholipids, and 
use (or not) of contact pathway inhibitors (CTI) and protein C pathway sensitizing agents 
[activated protein C (APC), thrombomodulin] because the experimental conditions providing 
the highest sensitivity and specificity for detecting hypercoagulability have not been defined. 
The goals of this study were to:  1) distinguish the effects of assay conditions (added TF, 
thrombomodulin, platelets/phospholipids) and elevated factor levels on thrombin generation 
parameters, and 2) determine the conditions and parameters with the highest sensitivity and 
specificity for detecting elevated factor levels.  We simulated “hypercoagulability” by 
spiking plasma with factors XI, IX, VIII, X, V, prothrombin, or fibrinogen to 200% and 
400% of normal, and measured the effect of these factors on thrombin generation parameters 
in different experimental conditions.  We report that the conditions under which CAT was 
performed differentially affected its sensitivity.  Changes in the peak height and/or ETP 
following initiation of clotting in PFP with 1 pM TF was most likely to detect 
hypercoagulability due to increased factor levels. 
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2.3  Materials and Methods 
 All proteins used in this study were of the highest quality and specific activity available.  
CTI and factors XI, V, and prothrombin were purchased from Haematologic Technologies, 
Inc (Essex Junction, VT).  Factor X and plasminogen-, von Willebrand factor- and 
fibronectin-depleted fibrinogen were purchased from Enzyme Research Laboratories (South 
Bend, IN); factor X was further purified as described.[5]  Factor VIII (Hemofil M, Baxter, 
Deerfield, IL) and factor IX were the generous gifts of Dr. Dougald M. Monroe (UNC at 
Chapel Hill).  Briefly, factor IX was prepared from prothrombin complex concentrations by 
Q Sepharose chromatography, heparin affinity, metal chelate chromatography using copper, 
and pseudo-affinity calcium elution from HiTrap Q.  Factor IX could be activated completely 
by factor XIa and gave the expected molar concentration when the activated material was 
titrated with antithrombin in the presence of heparin.   Protein purity was verified by both 
non-reducing and reducing 12% SDS-PAGE prior to use.  Analysis of factors XI, IX, X, V, 
prothrombin, and fibrinogen: 1) revealed only bands of the expected molecular weight for 
each zymogen and cofactor, and 2) indicated no activated protein species (data not shown).  
The factor VIII preparation (Hemophil M) also contained albumin, however, control 
experiments showed no effect of this albumin concentration on thrombin generation (data not 
shown).  The specific activity of the factor V preparation was 51.3 U/mg, consisted with that 
expected for factor V (50-60 U/mg), and ~40X lower than that expected for factor Va (2000 
U/mg), indicating no factor Va contamination in the preparation.  Rabbit lung 
thrombomodulin was from American Diagnostica, Inc (Stamford, CT).  Fluorogenic 
thrombin substrate (Z-Gly-Gly-Arg-AMC), TF/Lipid Reagents (PFP-Low, PFP-High), and 
thrombin calibrator (α2-macroglobulin/thrombin) were generously provided by Diagnostica 
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Stago (Parsippany, NJ).  Lipids were composed of phosphatidylserine, phosphatidylcholine, 
and phosphatidylethanolamine at a ratio of 20:60:20, respectively.  Blood was collected 
according to protocols approved by the UNC Institutional Review Board. 
 
Plasma preparations  
For PFP, blood was collected from 18 healthy individuals [20-45 years old, 50% female, 
50% non-Caucasian, with normal partial thromboplastin times (PTT)] through a 21-gauge 
needle into a syringe and immediately transferred to sodium citrate/CTI [0.105 M (3.2%, pH 
6.5) and 18.3 µg/mL, respectively] to minimize contact activation.[28, 29]  PFP was prepared 
by sequential centrifugation (150xg, 15 minutes, 13,000xg, 15 minutes), aliquoted, and snap-
frozen in liquid nitrogen within two hours of phlebotomy.  PFPs were then thawed, pooled, 
and refrozen for subsequent assays.  Pooled PFP was analyzed for levels of factors XI, IX, 
VIII, X, V, VII, protein C, free protein S, prothrombin, and fibrinogen at UNC Hospitals 
McLendon Clinical Laboratory; all were in the normal reference range. 
 For PRP, blood was collected from six healthy individuals (21-50 years old, 67% female, 
normal PTTs) who had not taken aspirin for two weeks or ibuprofen for three days prior to 
phlebotomy.  Blood was drawn as for PFP.  PRP was prepared by centrifugation (150xg, 15 
minutes) within one hour.  The platelet count was measured on a Z1 Series Coulter Counter 
(Beckman Coulter, Fullerton, CA), normalized by dilution with autologous PFP to 
225,000/µL, and used at 150,000/µL (final).   
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Thrombin generation assay  
Factors XI, IX, VIII, X, V, prothrombin and fibrinogen were added to normal, pooled 
PFP and individual PRPs to 200% or 400% of normal (final).  Thrombin generation was 
measured by CAT.[13]  For PFP experiments,  20 µL of TF/phospholipids were mixed with 
80 µL PFP in 96-well round-bottom microtiter plates (Becton Dickinson, Falcon™).  The 
plate was inserted into a Fluoroskan Ascent® fluorometer (ThermoLabsystem, Helsinki, 
Finland) and warmed to 37°C for 5 minutes.  Reactions were initiated by automatically 
dispensing 20 µL of 2.5 mM fluorogenic substrate in 0.1 M CaCl2 to each well.  Reactions 
were performed in duplicate or triplicate in each experiment.  The final TF, phospholipid, 
fluorogenic substrate, and CaCl2 concentrations were 1 or 5 pM, 4 µM, 416 µM and 16 mM, 
respectively.  Experiments with PRP were performed under identical conditions, but without 
added phospholipids.  Reactions were calibrated against wells containing 20 µL of α2-
macroglobulin/thrombin complex and 80 µL PFP or PRP.[13]  Thrombin generation was 
monitored at 37°C with excitation and emission filters at 390 nm and 460 nm, respectively, 
every 20 seconds for 120 minutes.   Experiments with PFP and 1 pM TF, PFP and 5 pM TF, 
and PRP and 1 pM TF were performed 10, 5, and 6 times, respectively. 
 Thrombin parameters were calculated using Thrombinoscope software version 3.0.0.29  
(Thrombinoscope BV, Maastricht, Netherlands), which defines the lag time (LT) as the first 
time point after the thrombin concentration exceeded one-sixth peak height, the TTP as the 
time to the peak height, the peak height as the maximum thrombin concentration produced, 
and the ETP as the time integral of thrombin formation (the area under the thrombin 
generation curve). 
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Statistical methods 
Statistical analysis was performed for logarithms of parameters using analysis of variance 
(ANOVA) that accounted for experiment date (PFP experiments), or donor (PRP 
experiments) and elevated factors.  Each condition (factor level) was handled separately; 
factor concentration was not considered a covariate.  An ANOVA model was first fit to each 
log-transformed parameter with covariates of date or donor, factor level, an indicator variable 
for platelets, and the interaction between factor level and platelet indicator.  We compared 
PFP initiated with 1 pM TF to:  1) PFP initiated with 5 pM TF, and 2) PRP initiated with 1 
pM TF.  Hypothesis testing was performed using a contrast matrix corresponding to a 1 
degree of freedom F-test for each parameter.  In a separate analysis, for each log-transformed 
parameter, a separate ANOVA model was fit with covariates of date or donor and factor 
level.  To determine the effect of thrombomodulin in the presence of elevated factors, 
ANOVA models were applied to the log of the ratio of the parameter value with and without 
thrombomodulin.  Differences in least square means between conditions and the control were 
evaluated by t-tests.  Multiple comparisons were handled with Bonferroni corrections; 
significance was p<0.0033 (0.05/15) unless otherwise indicated.  The percent coefficient of 
variation (%CV) was calculated as the ratio of the standard deviation to the mean multiplied 
by one hundred for inter-assay variability (PFP) and inter-individual variability (PRP). 
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2.4  Results 
Thrombin generation in normal PFP and PRP   
 We first characterized the effects of TF on thrombin generation in normal PFP and PRP.  
Thrombin generation in PFP required addition of both TF and phospholipids; omission of 
either prevented thrombin generation for >120 minutes (data not shown), indicating that the 
PFP was not contaminated with detectable endogenous TF activity, procoagulant lipids, or 
contact activation.  Similarly, thrombin generation in PRP required addition of TF (data not 
shown), indicating that PRP from these healthy subjects did not contain detectable TF 
activity or contact activation. 
 Table 2.1 shows baseline thrombin generation characteristics for PFP and PRP.  
Reactions initiated by 1 and 5 pM TF are indicated:  PFP(1 pM TF), PFP(5 pM TF), and PRP(1 pM 
TF), respectively.  Compared to PFP(1 pM TF), PFP(5 pM TF) demonstrated shortened LT and TTP 
and increased peak height and ETP.  The inter-assay variability (%CV) of PFP (Table 2.2) 
and inter-individual variability (%CV) in PRP (Table 2.3) were consistent with prior 
studies.[13, 26, 30]  Thrombin generation in PFP(1 pM TF) demonstrated a significantly shorter 
LT and TTP, increased peak height and decreased ETP than PRP(1 pM TF), consistent with 
previous studies.[13, 26, 30]  
 
Effect of thrombomodulin on thrombin generation in normal PFP and PRP 
 Thrombin generation in normal PFP is decreased in the presence of thrombomodulin or 
APC[3, 13, 22, 24, 31, 32]; however, patients with a protein C pathway deficiency (factor V 
Leiden, protein C/S deficiency) have decreased thrombomodulin/APC sensitivity.[22, 24]  
Previous studies have recommended that CAT assays include APC or thrombomodulin to  
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Table 2.1  Baseline characteristics (±SD) of thrombin generation in PFP and PRP, in 
the absence and presence of 5 pM thrombomodulin (TM).   
 PFP(1 pM TF) PFP(5 pM TF) PRP(1 pM TF) 
 -TM +TM -TM +TM -TM +TM 
LT (min) 4.5 ±0.4 5.3 ±0.5* 1.9 ±0.2^ 2.4 ±0.2* 9.7 ±2.9^ 13.1 ±4.4* 
TTP (min) 9.1 ±0.6 8.6 ±0.6* 4.4 ±0.3^ 4.5 ±0.2  20.4 ±2.9^ 22.0 ±4.8  
Peak height  197.0 ±30.2 35.9 ±16.8* 344.4 ±10.4^ 296.4 ±22.2* 132.2 ±37.6^ 52.6 ±15.6* 
ETP  1569.1 ±168.8 197.9 ±90.2* 1754.7 ±176.2^ 1303.9 ±128.7* 1893.6 ±455.3^ 602.1 ±94.9* 
*p<0.0001 vs. “-TM” 
^p<0.0001 vs. “PFP(1 pM TF)-TM” 
 
Table 2.2  Inter-assay Variability (%CV) of Thrombin Generation in PFP 
 
 
 
 
 
 
 
Table 2.3  Inter-individual Variability (%CV) of Thrombin Generation in PRP 
 PRP(1 pM TF) 
 -TM +TM 
LT 29.72 33.89 
TTP 14.36 21.94 
Peak height 28.39 29.65 
ETP 24.04 15.76 
 PFP(1 pM TF) PFP(5 pM TF) 
 -TM +TM -TM +TM 
LT 8.38 9.15 10.83 9.75 
TTP 6.41 6.96 5.81 5.25 
Peak height 15.35 46.81 3.03 7.49 
ETP 10.76 45.55 10.04 9.87 
  44 
increase ability to discriminate between healthy subjects and VTE patients, as well as predict 
VTE recurrence.[19, 23, 24, 31]  We first compared thrombin generation in the presence and 
absence of thrombomodulin in PFP(1 pM TF) and PFP(5 pM TF) (Figs 2.1a-2.1b, Table 2.1).  
Thrombomodulin significantly prolonged the LT and reduced the peak height and ETP in 
both PFP(1 pM TF) and PFP(5 pM TF).  Thrombomodulin significantly shortened the TTP in PFP(1 
pM TF), but not PFP(5 pM TF).  Increased TF decreased thrombomodulin sensitivity; that is, 5 nM 
thrombomodulin reduced the ETP ~87±1.9% and ~28±3.1% for PFP(1 pM TF) and PFP(5 pM TF), 
respectively.  Thrombomodulin significantly increased the inter-assay %CV of the peak 
height and ETP in PFP(1 pM TF), but had less effect in PFP(5 pM TF) (Table 2.2). 
 We then examined the impact of thrombomodulin on thrombin generation in PRP(1 pM TF).  
As in PFP(1 pM TF), thrombomodulin prolonged the LT and reduced the peak height and ETP in 
PRP(1 pM TF) (Fig 1c, Table I).  In contrast to PFP(1 pM TF), thrombomodulin slightly prolonged 
the TTP in PRP(1 pM TF), likely because the TTP in PRP is limited by the time to platelet 
activation.  These findings are somewhat different, although not altogether inconsistent with 
previous findings that thrombomodulin decreased ETP, but did not change LT or TTP in 
PRP.[13]  The differences in response to thrombomodulin in these studies may relate to the 
thrombomodulin source (human vs. rabbit lung), although another study found similar effects 
of thrombomodulin from different sources on ETP.[24]  The inter-individual variability 
increased for LT and TTP, decreased for ETP, and did not change for peak height in the 
presence of thrombomodulin (Table 2.3).  Platelets decreased CAT sensitivity to 
thrombomodulin; that is, 5 nM thrombomodulin reduced the ETP ~66±4.8% in PRP(1 pM TF), 
compared to ~87±1.9% in PFP(1 pM TF) (Fig 2.1c, Table 2.1).  The reduced thrombomodulin  
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Figure 2.1  Thrombomodulin decreases thrombin generation in PFP(1 pM TF), PFP(5 pM TF) 
and PRP(1 pM TF).  A, B) Thrombin generation in PFP was initiated by addition of 4 µM 
phospholipids and A) 1 pM TF or B) 5 pM TF.  C) Thrombin generation in PRP was initiated 
by addition of 1 pM TF.  Curves show increasing thrombomodulin:  0 (circles), 2.5 
(triangles), 5 (squares), 10 (diamonds), and 20 (crosses) nM, representative of 3 separate 
experiments. 
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sensitivity of PRP versus PFP likely reflects contributions of platelet-derived factor V(a) to 
thrombin generation[33, 34], and is consistent with previous studies.[13] 
 
Effect of procoagulant factors on thrombin generation in PFP and PRP 
Finally, we compared the ability to detect hypercoagulability under each of these 
conditions (1 and 5 pM TF, in the presence and absence of thrombomodulin, in PFP and 
PRP).  We measured thrombin generation in PFP and PRP spiked with factors XI, X, IX, 
VIII, V, prothrombin, or fibrinogen.  We initiated clotting in PFP with 1 or 5 pM TF and 4 
µM phospholipids, and in PRP with 1 pM TF (no phospholipids), in the presence and 
absence of thrombomodulin. 
LT:  The LT in PFP(1 pM TF) and PFP(5 pM TF) were qualitatively similar, although changes 
in PFP(5 pM TF) were smaller than changes in PFP(1 pM TF) (Fig 2.2a, 2.2b).  In both the absence 
and presence of thrombomodulin, intrinsic factors XI, IX, and VIII did not significantly alter 
the LT, although effects were slightly greater in the presence of thrombomodulin.  Factor X 
significantly shortened the LT in both conditions.  Interestingly, factor V significantly 
shortened the LT in PFP(1 pM TF) but not PFP(5 pM TF).  Both prothrombin and fibrinogen 
significantly increased the LT, irrespective of the TF concentration or presence of TM.  The 
opposing effects of factor X and prothrombin on LT in PFP may relate to differences in their 
plasma concentrations.  Whereas 200% factor X increases the plasma level from 8 to 16 
µg/mL, 200% prothrombin increases the plasma level from 100 to 200 µg/mL.  This high 
concentration of prothrombin or the prothrombin activation product fragment 1.2 may 
competitively inhibit binding of other Gla proteins to the lipid surface, thereby prolonging 
the time to complex assembly and enzyme generation.  Indeed, elevated prothrombin did not  
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Figure 2.2  Procoagulant factors and thrombomodulin differently influence LT in PFP 
and PRP.  PFP or PRP was spiked with factors XI, IX, VIII, X, V, prothrombin, or 
fibrinogen to 200% or 400% of normal.  Clotting was initiated by addition of 1 pM TF and 4 
µM phospholipids (circles), 5 pM TF and 4 µM phospholipids (diamonds), or 1 pM TF (no 
lipids, squares) for A) PFP(1 pM TF), B) PFP(5 pM TF), and C) PRP(1 pM TF), respectively, in the 
absence (open symbols) and presence (closed symbols) of thrombomodulin, as described in 
Methods.  Note y-axis scaling in panel C.  The shaded gray box encompasses the 100% value 
and its standard error of the mean (SEM).  Data show means ±SEM. *p<0.0033 versus 
100%. 
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prolong the LT in assays performed in the presence of increased (300 µM) lipid 
concentrations (data not shown). 
Procoagulant factors produced unique effects on the LT in PRP(1 pM TF) (Fig 2.2c).  In both 
the presence and absence of thrombomodulin, factors XI, IX, VIII, X, prothrombin, and  
fibrinogen non-significantly shortened the LT in PRP(1 pM TF); only 400% factor XI 
significantly shortened the LT.  These findings suggest that in contrast to PFP, the LT in PRP 
is predominated by the time required for platelet activation and supercedes the time 
necessary to form procoagulant complexes on exposed lipid.  Factor V exhibited a biphasic 
effect on LT in PRP(1 pM TF), significantly increasing the LT at 200%, with no effect at 400%.  
These interesting observations were unique to experiments with platelets and may reflect 
differences in the procoagulant activity of plasma and platelet-derived factor V(a).[34] 
 TTP:  Factors XI, IX, and VIII generally shortened the TTP in PFP(1 pM TF), but did not 
affect the TTP in PFP(5 pM TF) (Fig 2.3a, 2.3b).  Factor X shortened the TTP in both PFP(1 pM TF) 
and PFP(5 pM TF).  Factor V and fibrinogen produced little to no effect on TTP in either 
condition.  With the exception of prothrombin, the factors produced qualitatively similar 
effects in PRP(1 pM TF) as in PFP(1 pM TF), with a slight decrease in the TTP with factors XI, IX, 
VIII, X, and fibrinogen (Fig 2.3c).  Effects were similar in the presence and absence of 
thrombomodulin. 
 Interestingly, as seen in the LT, whereas prothrombin prolonged the TTP in PFP, it 
shortened the TTP in PRP.  Again, prothrombin’s effect may arise in PFP because of 
prothrombin binding to the constitutively exposed lipid surface of the synthetic lipids, 
whereas the lipid surface is protected from prothrombin binding on unactivated platelets until  
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Figure 2.3.  Procoagulant factors and thrombomodulin differently influence TTP in 
PFP and PRP.  Reactions were performed as in Fig 2.2.  A) PFP(1 pM TF), B) PFP(5 pM TF), C) 
PRP(1 pM TF).  The shaded gray box encompasses the 100% value ±SEM.  Data show means 
±SEM for the absence (open symbols) and presence (closed symbols) of thrombomodulin. 
Note y-axis scaling in panel C.  *p<0.0033 versus 100% 
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the time of activation.  Platelet activation permits simultaneous formation of both tenase and 
prothrombinase, preventing inhibition by high prothrombin concentrations. 
 Peak height:  In contrast to effects on LT and TTP, factors exhibited similar effects on 
peak height in PFP and PRP; however the magnitude of the effects differed substantially (Fig 
2.4a – 2.4c).  For all conditions, factors XI, IX, VIII, X, prothrombin, and fibrinogen  
increased the peak height, whereas factor V had little effect on peak height.  Changes were 
largest in PFP(1 pM TF), followed by PFP(5 pM TF) and PRP(1 pM TF), respectively, but similar in 
the presence and absence of thrombomodulin for all three conditions. 
 ETP:  As with peak height, factors similarly affected ETP in PFP and PRP; however, the 
magnitude of the effects differed substantially with the different conditions (Fig 2.5a – 2.5c).  
Factors IX, VIII, X, prothrombin, and fibrinogen increased the ETP in PFP(1 pM TF), PFP(5 pM TF), 
and PRP(1 pM TF).  Factor XI increased ETP only in reactions initiated with 1 pM TF, in the 
presence of thrombomodulin.  Factor V had little effect on ETP in any condition. 
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Figure 2.4.  Procoagulant factors and thrombomodulin differently influence peak height 
in PFP and PRP.  Reactions were performed as in Fig 2.2  A) PFP(1 pM TF), B) PFP(5 pM TF), C) 
PRP(1 pM TF).  The shaded gray box encompasses the 100% value ±SEM.  Data show means 
±SEM for the absence (open symbols) and presence (closed symbols) of thrombomodulin. 
Note the y-axis scaling.  *p<0.0033 versus 100% 
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Figure 2.5.  Procoagulant factors and thrombomodulin differently influence ETP in 
PFP and PRP.  Reactions were performed as in Fig 2.2  A) PFP(1 pM TF), B) PFP(5 pM TF), C) 
PRP(1 pM TF).  The shaded gray box encompasses the 100% value ±SEM.  Data show means 
±SEM for the absence (open symbols) and presence (closed symbols) of thrombomodulin. 
Note the y-axis scaling.  *p<0.0033 versus 100% 
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2.5 Discussion 
 Using a range of TF and phospholipid concentrations in the presence and absence of 
protein C pathway inhibitors, previous studies have correlated VTE risk with elevated peak 
height[18], ETP[20, 22-25] or both[19, 21].  Other studies have focused on the LT, rate, and 
peak as an indicator of circulating TF and prothrombotic disease.[19, 35, 36]  Although 
differences in findings between studies have been attributed to differences in assay 
conditions, few studies have contrasted different assay conditions within a single design, and 
even fewer under hypercoagulable conditions.  It has not been explicitly shown that all 
conditions provide equal sensitivity and specificity to detect hypercoagulability.  Given 
limited plasma sample sizes and limited availability of samples from large-scale 
epidemiologic studies of hypercoagulability, empirical evidence for the use of specific 
conditions and parameters is essential for designing prospective studies of plasma 
hypercoagulability.  Our study design permitted the direct comparison of conditions and 
parameters to identify those most sensitive and specific to factor-induced hypercoagulability.  
To our knowledge, this work is the first comprehensive, systematic comparison of these 
conditions in a single study.   
 Our analysis shows that in PFP, factors XI, IX, VIII, X, prothrombin, and fibrinogen 
significantly increased peak height and ETP, though increases were proportionally larger for 
peak height than ETP.  Whereas the baseline peak height of PFP(5 pM TF) was 74% higher than 
that of PFP(1 pM TF) (344 nM vs. 197 nM, respectively, Table 2.1), the apparent “maximum 
peak height” in PFP(5 pM TF) plus elevated factors XI, IX, VIII, X, or V up to 400% was only 
23% higher than that in PFP(1 pM TF) plus elevated factors (396 nM vs. 322 nM, respectively).  
These findings suggest that the maximum observable difference between peak height in 
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normal and “hypercoagulable” PFP was reduced in assays initiated with higher TF (15% for 
PFP(5 pM TF) vs. 63% for PFP(1 pM TF)).  Similarly, the maximum ETP in PFP(5 pM TF) with elevated 
factors XI, IX, VIII, X, or V (1925 nM*min) was only 3.8% higher than that in PFP(1 pM TF) 
(1854 nM*min).  Thus, the maximum observable difference in ETP between PFP and 
“hypercoagulable” PFP was reduced in PFP(5 pM TF) (9.7%) versus PFP(1 pM TF) (18%).  This 
difference is even smaller than that seen for peak height.  The exception to these results is in 
PFP containing elevated prothrombin.  Prothrombin (200%) significantly increased peak 
height and ETP in both in both low (1 pM) (1.29-fold and 1.60-fold, respectively) and high 
(5 pM) (1.36-fold and 1.66-fold, respectively) TF.  These findings suggest that the 
mechanism limiting thrombin generation in this system results, at least in part, from the 
prothrombin concentration and indicates that peak height and ETP are exquisitely sensitive to 
hyperprothrombinemia. 
 It is widely accepted that PRP may provide greater physiologic relevance in assays of this 
nature, however studies of PFP persist, in part because of logistical limitations associated 
with the use of fresh PRP.  Our study demonstrates that CAT assays of PFP and PRP show 
different trends in LT and TTP, but provide qualitatively similar data on peak height and 
ETP.  Thus, studies comparing the presence and absence of platelets are likely to provide 
consistent information on peak height and ETP, but inconsistent findings on LT and TTP.  
Differences in response of LT or TTP in PFP and PRP may, however, provide important 
mechanistic information on the role of platelets and platelet abnormalities in thrombosis. 
Epidemiologic studies have correlated factors XI, IX, VIII, X, prothrombin, and 
fibrinogen, but not factor V, with increased VTE risk.[6-12]  In this regard, CAT appears 
specific to hypercoagulability due to these factors.  It is important to note, however, that the 
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magnitude of change in thrombin generation did not correlate with the degree of thrombotic 
risk associated with each factor.  For example, elevated prothrombin produced a large linear 
increase in peak height.  However, thrombotic risk associated with elevated prothrombin is 
relatively small (OR ~2.1).[7]  Discrepancies between the thrombin generation measurements 
and clinical risk in the case of elevated prothrombin may result from difficulties in measuring 
(pro)thrombin concentrations in excess of the antithrombin level present in the plasma. 
Additionally, although 200% fibrinogen increased the peak height and ETP, its role in VTE 
risk is controversial.  It is unclear whether the effects of fibrinogen on thrombin generation 
parameters resulted from changes in thrombin generation, itself, or in the ability of 
fibrinogen (“antithrombin I”) to bind thrombin and preserve its proteolytic activity towards 
small molecular substrates.  Thus, CAT may demonstrate disproportionately high peak height 
and ETP for patients with lower overall risk, reducing the specificity and predictive value of 
this technique in certain patients.   
As a means of distinguishing effects of procoagulant factors on CAT, we noted that 
whereas several clotting factors significantly increased peak height and ETP, these factors 
had different and sometimes unique effects on other parameters.  For example, in PFP(1 pM TF), 
elevated levels of factors IX, X, and prothrombin significantly increased peak height and 
ETP.  However, factor IX did not affect the LT, factor X significantly decreased the LT, and 
prothrombin prolonged the LT in low but not high lipid concentrations (data not shown).  
Thus, analysis of multiple experimental conditions (e.g., varied lipid concentrations) and/or 
parameters may be helpful in discerning factors contributing to abnormal thrombin 
generation in certain PFPs.  Indeed, Tripodi et al. recently suggested that use of three 
abnormal thrombin generation parameters (LT, peak height, and ETP) improves the 
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identification of patients at risk of recurrent VTE versus analysis based on a single 
parameter.[37]  
 Comparisons of findings between centers have been difficult, as inter-center variability is 
high partly due to the use of “in house” reagents and protocols.  Using a particularly elegant 
study design, Dargaud et al. (2007) showed that the use of different TF and phospholipid 
sources produces large variability in CAT, but standardizing conditions significantly reduces 
center-to-center variability.[27]  We used commercially-available reagents from the CAT 
manufacturer, which may offer consistency in results and enable the continued evaluation of 
these conditions in future studies.  
 This study has several limitations.  First, although thrombomodulin may be helpful in 
characterizing plasmas with proteins C or S deficiency or factor V Leiden, the physiological 
thrombomodulin concentration has not been established because it is primarily a cell-
associated protein.  Thus, the concentration of soluble thrombomodulin that provides the 
most clinically-useful information has not been determined.  Our data suggested that 
thrombomodulin increased the inter-assay %CV and dampened the effects of 200% 
fibrinogen at low TF, but did not significantly impact the ability to detect hypercoagulability 
from the other factors tested.  Thus, its general use for detecting protein C pathway 
abnormalities is compatible with assays used to detect elevated levels of clotting factors.  
Second, although epidemiological studies have suggested elevated levels of certain clotting 
factors independently increase VTE risk[6-12], the factor levels we tested were generally 
higher than those reported in these studies.  Of note, however, prothrombin levels as high as 
500% of normal have been reported in patients with type 2 diabetes.[38]  CAT’s ability to 
detect elevated prothrombin suggests abnormal thrombin generation in these patients would 
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be readily detected by this technique.  Third, our study design compared frozen/thawed, 
pooled PFP with individual PRP, which may emphasize differences in %CV between PFP 
and PRP.  Fourth, as opposed to tests of individual factor levels, CAT offers the advantage of 
testing global hemostatic potential.  Effects of multiple abnormal coagulation factor levels on 
thrombin generation may be additive, synergistic, or reflect only the effects of the most 
limiting factor.  Additional studies are warranted to fully appreciate the effects of multiple 
factor abnormalities on thrombin generation measured with this technique.  Finally, it is not 
clear whether CAT recapitulates the in vivo pathologic effects of procoagulant factors; other 
mechanisms besides thrombin generation may contribute to thrombotic risk.  
 In sum, we have shown that CAT’s ability to detect elevated factors varies between 
factors and depends on the assay conditions.  The largest changes in thrombin generation in 
response to elevated factors XI, IX, VIII, X, and prothrombin were seen in peak height and 
ETP in PFP(1 pM TF).  Smaller changes were observed in PFP(5 pM TF) and PRP(1 pM TF).  
Therefore, monitoring the peak height and/or ETP following initiation of clotting in PFP with 
1 pM TF is most likely to detect hypercoagulability due to increased procoagulant factor 
levels. 
 Our findings support efforts to standardize reagents (TF and lipid concentrations)[27] to 
reliably achieve the assay conditions necessary for maximal sensitivity.  Our data also 
confirm effects previously seen in normal plasma, but importantly, extend these findings to 
hypercoagulable situations.  Identification of conditions that best identify hypercoagulability 
and predict VTE warrants further investigation.  In vivo, VTE risk likely depends on a 
combination of increased procoagulant and decreased anticoagulant activities, and/or other 
pathologic mechanisms.  In a clinical setting, the concerted use of several different assay 
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conditions may be necessary to identify patients with distinct clinical phenotypes, not unlike 
the use of both aPTT and PT to diagnose factor deficiencies.  
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Chapter 3 
 
Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to 
thrombolysis  
This chapter is based on and reproduced in part with permission from: 
Machlus KR, Cardenas JC, Church FC and Wolberg AS. Causal relationship between 
hyperfibrinogenemia, thrombosis, and resistance to thrombolysis. Blood, 2011, 
117(118):4953-4963 
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3.1  Abstract 
Epidemiologic studies have correlated elevated plasma fibrinogen (hyperfibrinogenemia) 
with risk of cardiovascular disease and arterial and venous thrombosis.  However, it is 
unknown whether hyperfibrinogenemia is merely a biomarker of the pro-inflammatory 
disease state or is a causative mechanism in the etiology.  We raised plasma fibrinogen levels 
in mice via intravenous infusion and induced thrombosis by ferric chloride application to the 
carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia 
significantly shortened the time to occlusion in both models.  Using immunohistochemistry, 
turbidity, confocal microscopy, and elastometry of clots produced in cell and tissue factor-
initiated models of thrombosis, we show that hyperfibrinogenemia increased thrombus fibrin 
content, promoted faster fibrin formation, and increased fibrin network density, strength, and 
stability.  Hyperfibrinogenemia also increased thrombus resistance to tenecteplase-induced 
thrombolysis in vivo.  These data indicate hyperfibrinogenemia directly promotes thrombosis 
and thrombolysis resistance, and does so via enhanced fibrin formation and stability.  These 
findings strongly suggest a causative role for hyperfibrinogenemia in acute thrombosis and 
have significant implications for thrombolytic therapy.  Plasma fibrinogen levels may be 
used to identify patients at risk for thrombosis and inform thrombolytic administration for 
treating acute thrombosis/thromboembolism.
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3.2  Introduction 
 Elevated plasma fibrinogen is associated with risk of cardiovascular disease and arterial 
and venous thrombosis.[1-9]  Several studies have detected dose effects, with increased risk 
of death or thrombosis in subjects with the highest plasma fibrinogen concentrations.[6-9]  
The Framingham[7] and Fragmin During Instability in Coronary Artery Disease (FRISC)[8] 
studies positively correlated fibrinogen levels with risk of cardiovascular disease and 
incidence of death and/or myocardial infarction, respectively.  The Leiden Thrombophilia 
Study (LETS) showed individuals with elevated fibrinogen levels (4.0-4.9 versus <3.0 
mg/mL, 130-160% of normal) have an adjusted odds ratio for venous thrombosis of 1.6, 
while individuals with ≥5 mg/mL fibrinogen (≥170% of normal) have a 4-fold higher 
thrombotic risk, even after adjusting for C-reactive protein levels.[9]  These epidemiologic 
studies suggest elevated fibrinogen is an independent risk factor for both arterial and venous 
thrombosis, and therefore a potential diagnostic and therapeutic target for predicting and 
reducing thrombosis. 
 Importantly, however, epidemiological studies have not and cannot show a causal 
relationship between fibrinogen and disease etiology.[2, 10, 11]  Fibrinogen levels increase 
with age, inflammatory processes, hematocrit, hypertension, glucose intolerance, cigarette 
smoking, and adiposity, and high fibrinogen levels increase plasma viscosity, a demonstrated 
risk factor for coronary heart disease.[5, 6, 12]  These potential confounders have not 
permitted distinction between fibrinogen’s role as a biomarker of inflammation or coincident 
co-morbidity and a direct, causative role in the etiology of cardiovascular disease. 
 Prior studies using animal models to clarify the role of hyperfibrinogenemia in 
thrombosis[13-17] have been equivocal and controversial.  Transgenic mice over-expressing 
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murine fibrinogen (~45% higher than wildtype) demonstrate elevated D-dimer and 
spontaneous fibrin deposition in the spleen, suggesting hyperfibrinogenemia is mildly 
prothrombotic.[15]  However, these mice demonstrate only marginal shortening of the time 
to 75% occlusion following 20% FeCl3 application to the carotid artery, indicating 
hyperfibrinogenemia is not important in arterial thrombosis.[15]  In contrast, rabbits treated 
with turpentine to elevate fibrinogen prior to stasis- or mechanical injury-induced venous 
thrombosis demonstrate a positive correlation between thrombus size, weight, and fibrin 
content.[16]  However, because turpentine also increases factor VIII, another thrombosis risk 
factor, the specific prothrombotic contribution of elevated fibrinogen is difficult to discern.  
One recent study in which the human gamma prime (γ’) chain of fibrinogen was expressed in 
transgenic mice suggested fibrinogen’s thrombin-binding properties are antithrombotic[17], 
further questioning a pathologic mechanism relating hyperfibrinogenemia to disease. 
 The aim of the current study was to determine whether elevated fibrinogen directly 
contributes to thrombosis and identify the operant mechanism(s).  We used in vivo models to 
assess fibrinogen’s effects on thrombus formation and stability, and cell and tissue factor 
(TF)-based ex vivo and in vitro methods to identify biochemical and biomechanical 
mechanisms by which fibrinogen modulates fibrin formation, structure, and function.  Our 
data indicate hyperfibrinogenemia directly and independently shortened the time to occlusion 
(TTO) and increased thrombus resistance to thrombolysis.  These effects were mediated 
through enhanced fibrin formation and increased fibrin network density and mechanical and 
fibrinolytic stability.  Together, these findings strongly suggest a causative role for 
hyperfibrinogenemia in the pathology of thrombosis.  Information on plasma fibrinogen 
levels may be used to identify patients at risk for thrombosis and inform thrombolytic 
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administration for treating arterial and venous thrombosis. 
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3.3  Materials and Methods 
Proteins and materials 
 Dulbecco’s Modified Eagle’s Medium with high glucose/2 mM L-glutamine, 0.05% 
trypsin and ethylenediamine tetraacetic acid (EDTA), and phosphate-buffered saline (10 mM 
phosphate pH 7.1, 150 mM NaCl, PBS) were from Gibco (Grand Island, NY).  Thrombin 
fluorogenic substrate (Z-Gly-Gly-Arg-AMC) and calibrator (α2-macroglobulin/thrombin) 
were from Diagnostica Stago (Parsippany, NJ).  Factor Xa chromogenic substrate 
(Pefachrome FXa) was from Pentapharm (Basel, Switzerland).  Mouse anti-human TF 
antibody (HTF-1) was the kind gift of Dr. Ronald Bach (University of Minnesota).  Tissue-
type plasminogen activator (tPA) and goat anti-mouse and anti-rabbit peroxidase-conjugated 
antibodies were from Calbiochem (La Jolla, CA).  Monoclonal anti-fibrin(ogen) antibody 
(59D8) was the generous gift of Drs. Marschall Runge [University of North Carolina (UNC) 
Department of Medicine] and Charles Esmon (Oklahoma College of Medicine).  Biotinylated 
secondary antibodies were from Vector Laboratories (Burlingame, CA).  Target Retrieval 
Solution was from Dako (Carpinteria, CA).  Non-immune mouse IgG antibody (MOPC-1), 
bovine serum albumin (BSA), and adenosine diphosphate (ADP) were from Sigma-Aldrich 
(Saint Louis, MO).  Recombinant human tumor necrosis factor α (TNFα) was from Millipore 
(Temecula, CA).  Corn trypsin inhibitor (CTI) and factor X were from Haematologic 
Technologies Inc (Essex Junction, VT).  Fibronectin-, plasminogen- and von Willebrand 
factor (vWF)-depleted fibrinogen was from Enzyme Research Laboratories (South Bend, 
IN).  Fibrinogen was further depleted of factor XIII by immunoaffinity chromatography.  The 
AlexaFluor-488 protein labeling kit was from Invitrogen (Carlsbad, CA).  AlexaFluor-488-
labeled fibrinogen (~8 mole fluorophore/mole fibrinogen) was prepared as described.[18]  
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Thrombin receptor activation peptide (Serine-Phenylalanine-Leucine-Leucine-Arginine-
Asparagine, TRAP) was from Bachem (Torrance, CA).  Collagen was from Chrono-Log 
(Havertown, PA).  Tenecteplase (TNKase) was the generous gift of Genentech (San 
Francisco, CA).  Contact-inhibited normal pooled plasma (NPP) was prepared from whole 
blood from 40 healthy subjects (50% female, 68% non-Caucasian) in a protocol approved by 
the UNC Institutional Review Board.[19]  The fibrinogen concentration in human NPP (3 
mg/mL) was determined by enzyme-linked immunosorbent assay. 
 
Murine Thrombosis and Thrombolysis Models 
 Procedures were approved by the UNC Institutional Animal Care and Use Committee.  
Mice (6-8 week old male C57BL/6, Charles River Laboratories, Raleigh, NC) were 
anesthetized with 1.5-2% isofluorane in 2% oxygen, and the left saphenous vein was exposed 
under a SZX12 dissecting microscope (Olympus, Tokyo, Japan) using a catheter constructed 
of pulled PE-10 tubing (Braintree Scientific, Braintree, MA) with a 3.0-mil (0.076 mm 
diameter) cleaning wire (Hamilton, Reno, NV) placed into the lumen as a stylet, as 
described.[20]  Human fibrinogen or vehicle [20 mM N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid pH 7.4, 150 mM NaCl (HBS) or HBS/BSA] was administered through 
the cannula on a per weight basis [blood volume (mL) is 7% of body weight (g), plasma is 
50% of blood volume] to achieve 135 or 170% of normal (endogenous murine fibrinogen 
plus infused human fibrinogen) in murine circulation 5 minutes prior to injury.  Final plasma 
fibrinogen levels were measured as described[21] in mice not subject to ferric chloride 
(FeCl3) injury.  Nanobead diffusion experiments showed these fibrinogen concentrations did 
not alter plasma viscosity (R. Spero, unpublished observation September 2010). 
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 For carotid artery thrombosis, the right common carotid artery was exposed after midline 
cervical incision.  A Doppler transonic flow probe (Transonic Systems, Ithaca, NY) was 
applied and connected to a flow meter (model T206, Transonic Systems, Ithaca, NY) 
supplying a data acquisition system (PowerLab 4/30 model ML866, AD Instruments, 
Australia).  The carotid artery was dried and 10% FeCl3 (0.62 M FeCl3 on 0.5x0.5 mm filter 
paper) placed on the artery for 3 minutes, removed, and tissues washed 3 times with warm 
saline.  Following injury, blood flow was continuously monitored.  For saphenous vein 
thrombosis, the saphenous vein of the right leg was dissected and exposed, 5% FeCl3 (0.31 M 
FeCl3 on 0.5x2 mm filter paper) placed on the vein for 3 minutes, removed, and tissues 
washed 3 times with warm saline.  Blood flow was monitored auditorily by Doppler 
ultrasonic flow probe.  In both models, the TTO was the time between FeCl3 administration 
and lack of flow for 60 consecutive seconds.  Experiments were stopped at 45 minutes if no 
occlusion occurred.  Occluded vessels were excised and fixed in 10% formalin. 
 Thrombolysis was assessed in mice subject to FeCl3 carotid artery thrombosis.  After 5 
consecutive minutes of blood flow below 0.1 mL/min, mice were infused with TNKase (0.5–
5 mg/kg) through the saphenous vein intravenous catheter while continuously monitoring 
carotid blood flow.  
  
H&E Staining and Immunohistochemistry 
 Fixed tissues were dehydrated and paraffin-embedded, and consecutive, 5 µm sections 
cut and mounted with vectamount (UNC Lineberger Comprehensive Cancer Center Animal 
Histopathology Core).  Slides were stained with hematoxylin and eosin to visualize the 
thrombus, and imaged with a Retiga 400R camera (Q imaging) linked to an Olympus Bx 61 
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microscope with a 20x U Plan FL N, 0.5 NA objective lens.  A computer equipped with 
Velocity software (v5.5) was used to operate the system.  Images were analyzed with Adobe 
Photoshop CS (v8.0).  For immunohistochemistry, antigen retrieval was performed in Target 
Retrieval Solution in a 95° C water bath.  Slides were stained with anti-fibrin antibody 
(59D8, 1:1000) that detects both human and mouse fibrin(ogen) ([15, 22], Figure 3.1) for 1 
hour at room temperature in a humidity-controlled chamber and developed using avidin-
biotin complex (Dako).  Negative controls were stained simultaneously in the absence of 
primary antibody.  Staining intensity of thrombi from at least four representative sections per 
mouse were analyzed by three independent, blinded observers on a scale of 0-3.  
 
Platelet Aggregation  
 Human platelet-rich plasma (PRP) obtained by centrifugation (150xg, 15 minutes) of 
citrated blood was adjusted to 250x103 platelets/mL with autologous platelet-poor plasma 
(PPP).  Aggregation was triggered by TRAP (50 µg/mL, final), collagen (2 µg/mL, final), or 
ADP (2.5 µM, final).  Light transmission was recorded on a Chrono-Log Optical 
Aggregometer 470. 
 
Cell culture 
 Primary human saphenous vein endothelial cells (HSVEC, PromoCell, Heidelberg, 
Germany) and human smooth muscle cells (SMC, Lonza Walkersville, Walkersville, MD), 
were cultured as directed to 80-95% confluence in 5% CO2 at 37°C.  Cells were used 
between passages 3-6 to reduce phenotypic drift. 
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Figure 3.1.  59D8 recognizes both human and mouse fibrin.  Human or mouse fibrinogen  
(0.5 mg/mL, final) was clotted with human thrombin (5 nM, final) in the presence of 10 mM 
CaCl2.  Clots were then dissolved in 12.5 mM EDTA and 40 mM dithiothreitol in 8 M urea 
for 1 hour at 60°C.  Human (lanes 1 and 2) or mouse (lanes 3 and 4) fibrin [3.7 (lanes 1 and 
3) or 7 (lanes 2 and 4) µg] samples were separated by SDS-PAGE on a 4-12% Tris-Glycine 
gel under reducing conditions.  Samples were electro-transferred to nitrocellulose, blocked 
overnight in TBS/1% Tween-20 and then incubated for one hour with the primary antibody 
against fibrin(ogen), 59D8 (1:250 dilution). 
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Cellular activity assays 
 TF activity was measured by chromogenic substrate cleavage on a SpectraMax Plus340 
plate reader (Molecular Devices, Silicon Valley, CA) in the presence and absence of 
inhibitory anti-TF antibody (HTF-1, 10 µg/mL) or isotype control (MOPC-21, 10 µg/mL), as 
described.[19]  Thrombin was measured by calibrated automated thrombography using a 
Fluoroskan Ascent fluorometer (ThermoLabsystem, Waltham, MA) as described.[19]  
Thrombin generation was calculated using Thrombinoscope software Version 3.0.0.29 
(Thrombinoscope BV, Maastricht, Netherlands).  The thrombin generation rate was 
calculated by dividing peak height by the difference from time to peak to lag time.  The 
endogenous thrombin potential is not reported because thrombin generation curves did not 
always return to baseline. 
 
Phospholipid vesicles   
 Phosphatidylcholine (egg), phosphatidylethanolamine (soy), and phosphatidylserine 
(porcine brain) were from Avanti Polar Lipids (Alabaster, AL).  Large unilamellar vesicles 
(41% phosphatidylcholine /44% phosphatidylethanolamine/15% phosphatidylserine) were 
made as described.[23]  Briefly, lipids were combined, dried under nitrogen gas, and 
resuspended in cyclohexane.  Resuspended lipids were lyophilized, resuspended in HBS 
containing 1 mM EDTA, and extruded through a 0.2 µm filter ten times. 
 
Clot formation and lysis by turbidity 
 For human plasma experiments, recalcified (16 mM, final), lipidated (4 µM, final) NPP 
was spiked with fibrinogen to 4.5, 6, or 7.5 mg/mL (150%, 200%, and 250% of normal, 
  74 
respectively), final, and immediately added to washed cell monolayers (67.7% plasma, final).  
For mouse plasma experiments, recalcified (16 mM, final) murine PPP containing 2.4 ± 0.2 
mg/mL fibrinogen (100%) was spiked with human fibrinogen to approximately 180% and 
270% of normal, diluted 1:3 in HBS, and clotted with TF (Innovin 1:30,000 final).  
Fibrinolysis assays included tPA (250 ng/mL, final) or TNKase (concentrations indicated) at 
the reaction start.  Clotting and lysis were detected by turbidity at 405 nm in a SpectraMax 
Plus340 plate reader.[18, 19] 
 
Laser scanning confocal microscopy (LSCM) 
 Clots were formed over washed cells in Lab-Tek II Chamber #1.5 coverglasses (Nalge 
Nunc International, Rochester, NY) with addition of AlexaFluor-488–labeled fibrinogen as 
described.[18, 19]   Clotting proceeded until a constant final turbidity was reached in 
separate, parallel reactions.  Clots were imaged on a Zeiss LSM5 Pascal laser scanning 
confocal microscope (Carl Zeiss, Inc) linked to a Zeiss Axiovert 200M microscope equipped 
with a Zeiss 63x 1.4 NA oil immersion plan apo-chromatic lens, as described.  The 488 nm 
line of a medium power multi-line argon ion laser was used for excitation and a 505-530-nm 
band-pass filter for emission. A computer equipped with Carl Zeiss software (v1.5) was used 
to operate the system. Optical sectioning was achieved by closing the pinhole in the front of 
the detector to one airy unit. The zoom factor was 1. Thirty optical sections (1024x1024 
pixels) in 3 randomly-chosen locations were collected at 0.36-µm intervals in the z-axis at the 
cell surface.  Image volumes were 146 x 146 x 10 µm.  Single images were collected in 15.47 
seconds. Optical resolution was ~0.14 um in the xy-plane and ~0.5 um on the z-axis. The 
sectioning interval in z was smaller than the calculated z- axis optical section resolution to 
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achieve Nyquest sampling in z based on the Zeiss software calculation.  Images were 
deconvolved using 3-dimensional deconvolution algorithms in AutoQuant's Autodeblur 
(Version x1.4.1; Media Cybernetics Inc., Bethesda, MD).  Fibrin network density was 
analyzed using ImageJ (1.37V; National Institutes of Health) by placing random grids of 2 
pixel crosses on individual slices (121-144 crosses/slice) and counting fibers intersecting the 
middle of the crosses divided by the total number of crosses, less crosses in the volume 
occupied by the cells, as described.[18, 19] 
 
Clot viscoelastometry  
 Human PRP and PPP from blood drawn into 3.2% sodium citrate/18.3 µg/mL CTI was 
recalcified (16 mM, final) and spiked with fibrinogen or BSA in HBS.  PRP and PPP had 
>300x103 and <8x103 platelets/mL, respectively.  The baseline PRP and PPP fibrinogen 
concentration was estimated in accord with NPP determinations.  PRP was clotted with TF (1 
pM, final), which corresponds to the TF activity of TNF-α-stimulated HSVEC (TNFα-
HSVEC).  PPP was clotted with 1 pM TF and 4 µM phospholipid.  Lysis assays were 
performed in the presence of tPA (500 ng/mL, final).  Clot elastic modulus (CEM) was 
measured by Hemodyne HAS™.[24] 
 
Statistical Methods 
 For TTO and immunohistochemistry, normal and hyperfibrinogenemic conditions were 
compared by Mann-Whitney test.  For CEM, normal and hyperfibrinogenemic conditions 
were compared by unpaired Student’s t tests.  For clotting assays, fibrin density, and 
fibrinolysis parameters, significant differences between groups were identified by one-way 
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analysis of variance and analyzed by Dunnett’s post-hoc test using 3 mg/mL fibrinogen as 
the index group (on unstimulated HSVEC, SMC or TNFα-HSVEC as indicated) to limit 
Type I error.  Statistical analyses were performed using Kaleidagraph v4.1 (Synergy 
Software, Reading, PA). 
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3.4  Results 
Hyperfibrinogenemia shortens the time to vessel occlusion after FeCl3 injury. 
 To determine the contribution of elevated fibrinogen to intravascular thrombus formation, 
we utilized two murine thrombosis models based on FeCl3 application to the carotid artery 
(high shear) or saphenous vein (lower shear) following intravenous infusion of human 
fibrinogen.  This infusion-based approach enabled us to precisely control the plasma 
fibrinogen level during thrombus formation.  Control experiments and published studies 
demonstrate human fibrinogen is incorporated into murine clots, supports murine platelet 
aggregation[25], and has appropriate half-life[26] in mouse circulation.  The endogenous 
fibrinogen concentration in mice was 2.4±0.2 mg/mL (100%) and levels were raised to 
3.2±0.2 or 4.0±0.1 mg/mL, final (135 or 170% of normal, respectively), consistent with 
levels associated with thrombosis in humans.[7, 9] 
 Consistent with transgenic hyperfibrinogenemic mice[13, 15] and a prior study in which 
human fibrinogen was injected into BALB/c mice[26], elevated fibrinogen did not trigger 
spontaneous thrombosis (Figure 3.2).  FeCl3 application to the carotid artery or saphenous 
vein of HBS-infused mice produced occlusive thrombi in 9.3 and 17 minutes (median 
values), respectively, confirming the prothrombotic effect of vascular disruption.  Infusion of 
control protein (BSA) did not further shorten the TTO in either vessel (data not shown).  
Mice infused with fibrinogen to 3.2±0.2 mg/mL (135%) demonstrated a non-significant trend 
to shorter TTO in the carotid artery model (data not shown); we did not test this fibrinogen 
concentration in the saphenous vein model.  Interestingly, compared to control (HBS or BSA 
infusion), fibrinogen infusion to 4.0±0.1 mg/mL final (170%) prior to FeCl3 injury  
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Figure 3.2  Elevated fibrinogen shortens the time to vessel occlusion following FeCl3 
injury.  Wildtype C57Bl/6 mice were infused with HBS or fibrinogen (plasminogen-, 
fibronectin-, and vWF-depleted or plasminogen-, fibronectin-, vWF-, and factor XIII-
depleted) to 170% of normal.  Thrombosis was induced by FeCl3 application to the carotid 
artery (A) or saphenous vein (B), and the TTO was determined by flow probe or Doppler, 
respectively.  In vessels that did not occlude, the TTO was recorded as 45 minutes.  Each 
point represents a separate mouse.  Lines show median values. 
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significantly (p<0.005) shortened the TTO in both carotid artery and saphenous vein models 
(6.4 and 14.2 minutes (medians), respectively, Figure 3.2).  The shortened TTOs were not 
due to factor XIII in the fibrinogen preparation; infusion of factor XIII-depleted fibrinogen 
also significantly (p<0.05) shortened the TTO versus control mice (Figure 3.2).  These data 
demonstrate a direct contribution of hyperfibrinogenemia to thrombus formation following 
vascular injury.   
 
Elevated fibrinogen increases the fibrin(ogen) content of thrombi. 
 To probe the mechanism for the shortened TTO, we first examined the morphology of 
thrombi formed in the murine carotid artery and saphenous vein.  H&E staining showed 
extensive, occlusive thrombi containing distinct regions of proteinaceous material and 
erythrocytes in injured vessels from both control and fibrinogen-injected mice (Figures 3.3A, 
3.3B).  Immunohistochemistry of thrombi in carotid artery and saphenous vein thrombi from 
control (HBS or BSA-infused) mice demonstrated weak fibrin staining concentrated 
primarily at the luminal edge of proteinaceous regions.  No staining was detected in the 
absence of primary antibody, confirming that the secondary antibody did not bind mouse 
tissue non-specifically (Figure 3.3A, 3.3B).  Staining was slightly more intense in thrombi 
from saphenous vein than carotid artery, consistent with higher fibrin production in lower 
shear conditions.[27]  Both carotid artery and saphenous vein thrombi from mice infused 
with human fibrinogen demonstrated more intense fibrin staining at the periphery of 
proteinaceous regions and intense, diffuse staining in regions containing erythrocytes 
(Figures 3.3C, 3.3D).  These findings suggest hyperfibrinogenemia increased thrombus fibrin 
content in both high and low shear vessels. 
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Figure 3.3.  Elevated fibrinogen increases fibrin(ogen) incorporation into thrombi 
following FeCl3 injury.  Representative sections through thrombi following FeCl3 injury to 
the carotid artery (A) or saphenous vein (B).  H&E staining shows regions of protein and 
packed erythrocytes.  Immunohistochemistry (IHC) for fibrin (59D8) on corresponding 
sections shows darker staining for fibrin(ogen) at the thrombi margins and in thrombi from 
hyperfibrinogenemic (170% fibrinogen) mice.  “No 1° Ab” indicates antibody 59D8 was 
omitted from IHC as a negative control.  Staining intensity (on a scale of 0-3) was 
normalized to assign the value of ‘3’ to the most intensely stained section in each vessel, 
separately.  Mean staining intensity from immunohistochemistry images from three separate 
carotid arteries (C) or four separate saphenous veins (D) for each condition was determined 
as described in Methods and compared to control (wildtype) carotid artery (p=0.1) and 
saphenous vein (*, p<0.05), respectively. 
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In vitro platelet aggregation is not increased by elevated fibrinogen levels.   
 We then tested whether hyperfibrinogenemia increased platelet aggregation, a process 
dependent on fibrinogen binding to platelet αIIbb3.  The endogenous fibrinogen 
concentration of human plasma was 3 mg/mL (100%), and fibrinogen levels were raised with 
additional human fibrinogen as indicated.  As shown in Figure 3.4 and Table 3.1, elevated 
fibrinogen did not increase, and even slightly decreased, platelet aggregation induced by 
TRAP, collagen, or ADP, consistent with a mechanism where high fibrinogen promotes full 
occupancy of platelet αIIbβ3 and inhibits inter-platelet bridging.[28]  These data suggest the 
mechanism by which hyperfibrinogenemia shortened the TTO was not via enhanced platelet 
aggregation. 
 
Both cellular procoagulant activity (PCA) and elevated fibrinogen increase fibrin 
formation.   
 We next determined the effect of fibrinogen level on fibrin formation in models of 
vasculature by incubating cultured cell monolayers with recalcified NPP spiked with 
fibrinogen.  We used unstimulated HSVEC to model unperturbed endothelium and SMC to 
model FeCl3-injured vessels.  We also used TNFα-HSVEC (100 ng/mL TNFα for 6 hours) to 
model intact cytokine-stimulated endothelium thought to promote clotting in venous 
thrombosis (Figure 3.5).  While quiescent endothelial cells in vivo do not express significant 
TF, cultured unstimulated endothelial cells exhibit low TF activity.[19]  However, the net 
PCA of cultured HSVEC was significantly lower than cultured SMC or TNFα-HSVEC 
(Figure 3.5, Table 3.2).   
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Figure 3.4  Fibrinogen does not increase platelet aggregation.  Platelet aggregation in 
human PRP obtained from citrated whole blood spiked with human fibrinogen (final 
concentrations indicated in the figure) was triggered by addition of 50 µg/mL TRAP (A), 2 
µg/mL collagen (B), or 2.5 µM ADP (C) and monitored by turbidity as described in 
Methods.  Graphs shown are from one experiment, representative of 4-6 experiments with 
each agonist. 
 
 
 
 
Table 3.1.  In vitro aggregation of human platelets is not enhanced in the presence of 
elevated fibrinogen. 
 TRAP Collagen ADP 
Fibrinogen 
(mg/mL) 
3 4.5 7.5 3 4.5 7.5 3 4.5 7.5 
Lagtime (s) 13.4±3.8 11.9±2.3 10.7±2.7 78.1±22 67.7±16 62.0±20 19±1.2 21.3±1.5 21.3±2.2 
Rate (%/s) 77.9±8.8 70.4±8.8 61.3±15 90.1±25 77.1±21 *60.3±23 54.5±11 51.3±8.4 45.8±5.9 
Maximum 
Amplitude 
(%) 
92.3±13 88.0±12 74.9±20 79.6±17 74.0±18 68.6±22 81.0±6.6 74.5±12 68.5±11 
Differences between groups were identified by a one-way analysis of variance and analyzed 
by unpaired Student’s t tests using 3 mg/mL fibrinogen as the index group. *P < 0.05 vs. 3 
mg/mL fibrinogen.  Data show mean±SD 
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Figure 3.5  TNFα  upregulates TF activity on HSVEC in a dose- and time-dependent 
manner.  HSVEC were incubated with A) TNFα (0-10 µg/mL) for 6 hours, or B) 100 ng/mL 
for 0-24 hrs.  Factor Xa generation (±SD) was measured by incubating cells with factors VIIa 
and X in the presence of CaCl2 and absence (open circles) or presence (closed circles) of 
anti-TF inhibitory antibody (HTF-1), and measuring factor Xa by chromogenic substrate in 3 
separate experiments.  Data were converted to TF activity by comparison with a standard 
curve. 
 
 
 
 
Table 3.2  TF activity and thrombin generation supported by HSVEC, SMC, and 
TNFα-HSVEC 
 HSVEC SMC TNFα-HSVECA 
TF Activity    
-HTF1 (pM/min) 0.073±0.012 *12.08±0.443 *3.141±0.459 
+HTF1 (pM/min) 0.075±0.007 0.973±0.021 0.066±0.066 
Thrombin Generation    
Lag Time (min) 41.9±12.1 *2.7±0.2 *6.1±1.7 
Rate (nM/min) 11.5±5.0 *77.1±16.6 21.0±1.7 
Time to Peak (minutes) 48.0±11.6 *6.8±0.6 *11.6±1.3 
Peak Height (nM) 54.1±21.6 *274.5±48.6 *113.9±10.9 
AHSVEC treated with 100 ng/mL TNFα for 6 hours 
*P < 0.05 vs. unstimulated HSVEC 
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 These experiments demonstrated unique effects of cellular PCA and fibrinogen level on 
fibrin formation (Figures 3.6A-C).  Relative to unstimulated HSVEC, increased PCA of 
SMC and TNFα-HSVEC (Figure 3.5, Table 3.2) significantly (p<0.002) shortened the fibrin 
formation onset (Figure 3.6D), consistent with the premise that exposure of procoagulant 
cells to blood triggers clotting.  Elevated fibrinogen trended toward a shortened clotting onset 
in reactions induced by unstimulated HSVEC, but did not reach statistical significance due to 
large variability.  In addition, fibrinogen did not further shorten the onset in reactions 
triggered by the more procoagulant SMC or TNFα-HSVEC.  Elevated fibrinogen did, 
however, significantly (p<0.001) increase peak turbidity (Figure 3.6E), indicating increased 
fibrin(ogen) incorporation into clots.  Interestingly, relative to NPP clots produced by 
unstimulated HSVEC, both cellular PCA [SMC (p=0.08) and TNFα-HSVEC (p<0.02)] and 
hyperfibrinogenemia (p<0.001) increased the fibrin formation rate (Figure 3.6F).  We 
observed a similar increase in the rate and final turbidity of TF-initiated clotting of murine 
plasma spiked with human fibrinogen (Figure 3.6G).  This increase in the rate and amount of 
fibrin production is consistent with the shortened TTO observed in the murine thrombosis 
model (Figure 3.2). 
 
Both cellular PCA and elevated fibrinogen increase fibrin network density. 
 We and others have previously correlated fibrin formation parameters with fibrin network 
structure.[18, 19, 29, 30]  To assess the impact of elevated fibrinogen on fibrin structure, we 
used LSCM to examine NPP clots produced by unstimulated HSVEC, SMC, and TNFα-
HSVEC with increasing fibrinogen concentrations.  Clots produced by SMC and TNFα-
HSVEC were composed of more densely-packed fibers (p<0.05) than those produced by  
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Figure 3.6  Both cellular PCA and elevated fibrinogen promote fibrin formation.  A-F) 
Recalcified (16 mM, final) human NPP spiked with fibrinogen or HBS was added to 
confluent cell monolayers.  Fibrin polymerization was measured by turbidity at 405 nm.  
Panels A-C show polymerization curves representative of four independent experiments with 
human NPP and unstimulated HSVEC (A), SMC (B), and TNFα-HSVEC (C).  Insets expand 
the x-axis (time) for each panel.  Symbols are: 3 (open circles), 4.5 (closed circles), 6 (closed 
squares), and 7.5 (closed diamonds) mg/mL fibrinogen, final.  Panels D-F show the onset, 
final turbidity, and fibrin formation rate (mean±SD) of all four experiments with human 
NPP, respectively.  *:  p<0.05 versus 3 mg/mL fibrinogen on HSVEC, #: p<0.05 versus 3 
mg/mL within each cell type.  G) Recalcified murine PPP was spiked with human fibrinogen 
or HBS, diluted 1:3 in HBS, and clotting was initiated with TF addition (Innovin 1:30,000 
final) and monitored by turbidity at 405 nm.  Symbols are:  2.4 (open circles), 4.4 (closed 
triangles), or 6.4 (closed inverted triangles) mg/mL fibrinogen, final.  Polymerization curves 
are from a single experiment representative of four independent experiments. 
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unstimulated HSVEC (Figure 3.7), consistent with observations that high thrombin 
generation promotes formation of dense networks of thin fibers.[18, 19, 29]  Notably, fibrin 
network density also correlated positively and significantly (p<0.001) with fibrinogen 
concentration in both human (Figures 3.7A, B) and murine (Figure 3.7C) plasmas, suggesting 
elevated fibrinogen levels promote formation of abnormally dense fibrin networks. 
 
Elevated fibrinogen increases clot mechanical strength. 
 Fibrin network structure determines clot viscoelasticity[24, 30], suggesting elevated 
fibrinogen alters clot mechanical properties.  To assess the impact of fibrinogen level on clot 
elasticity, we measured the CEM in clots forming in human PRP or PPP spiked with 
fibrinogen to 6 mg/mL, final (200%) or BSA (control).  Because these assays cannot be 
initiated by cell monolayers, we initiated reactions with 4 µM phospholipid and 0 (to model 
unstimulated endothelium) or 1 (to model vascular disruption) pM TF.  No CEM developed 
in the absence of added TF reflecting the requirement for a procoagulant stimulus (i.e., 
vascular disruption) to initiate clotting, even in hyperfibrinogenemic conditions.  Initiation of 
clotting by TF showed a significant (p<0.05) fibrinogen-dependent increase in peak CEM in 
both PRP and PPP (Figure 3.8A) suggesting elevated fibrinogen increases the structural 
integrity (mechanical strength) of the clot. 
 
Elevated fibrinogen increases plasma clot resistance to fibrinolysis. 
 Fibrin network density also determines a clot’s resistance to fibrinolysis.[18, 19, 31]  To 
evaluate the effect of elevated fibrinogen on clot resistance to fibrinolysis, we utilized both 
turbidimetric and mechanical (elastometry) lysis assays.  We first initiated clotting by  
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Figure 3.7 Both cellular PCA and the fibrinogen level modulate fibrin network density.  
A and B) Clots were formed by incubating unstimulated HSVEC, SMC and TNFα-
stimulated HSVEC monolayers with recalcified human NPP spiked with human fibrinogen 
or BSA, as indicated, and imaged by LSCM as described.[18, 19]  A) Representative 
micrographs  (146x146 µm, xy) show three-dimensional projections from 10 µm stacks at the 
cell surface (n≥3).  Darker areas show increased fibrin density.  B) Fibrin network density 
(mean±SD) of clots was determined as described in Methods. *:  p<0.05 versus 3 mg/mL 
fibrinogen on HSVEC, #: p<0.05 versus 3 mg/mL within each cell type.  C) Clots were 
formed by addition of TF (1:30,000 Innovin) to recalcified murine PPP spiked with human 
fibrinogen or HBS. 
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Figure 3.8  Elevated fibrinogen increases clot stability.  A) Human PRP and PPP prepared from 
CTI-inhibited whole blood was spiked with fibrinogen (to 6 mg/mL final, 200%) or BSA, recalcified, 
and clotted with TF (Methods).  Bars show peak CEM (mean±SD).  B-D) Recalcified human NPP 
spiked with fibrinogen or control was added to confluent cell monolayers.  Fibrin polymerization was 
initiated in the presence of tPA; clotting and lysis were measured by turbidity at 405 nm.  Panels B-D 
show representative turbidity curves with human NPP and unstimulated HSVEC (B), SMC (C), and 
TNFα-HSVEC (D).  Symbols are: 3 (open circles), 4.5 (closed circles), 6 (closed squares), and 7.5 
(closed diamonds) mg/mL fibrinogen, final.  E) Time to peak turbidity and F) peak turbidity 
(mean±SD, n=4), respectively.  *:  p<0.05 vs 3 mg/mL fibrinogen on HSVEC, #: p<0.05 vs 3 mg/mL 
within each cell type.  G) Recalcified murine PPP was spiked with human fibrinogen or HBS to 
achieve 2.4 (open circles), 4.4 (closed triangles), or 6.4 (closed inverted triangles) mg/mL fibrinogen, 
final, diluted 1:3 in HBS, and clotting was initiated with TF (Innovin 1:30,000 final) and monitored 
by turbidity.  Figure shows representative polymerization curves (n=2).  H) Representative 
elastometry curves (n=3) of human PRP and PPP prepared from CTI-inhibited whole blood, spiked 
with human fibrinogen (to 6 mg/mL, final) or BSA, recalcified and clotted with TF in the presence of 
tPA (Methods).  The longer initiation phase of PRP clots versus PPP clots reflects the time to platelet 
activation.[32] 
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Table 3.3  Elevated fibrinogen increased clot elastic modulus during lysis.   
 
 
Data are presented as fold increase over PPP or PRP with no additional fibrinogen. *P < 0.05 
vs. no additional fibrinogen 
 Peak CEM Area Under Curve Half-lysis 
PPP 1 1 1 
PPP+Fibrinogen *2.7±0.6 *3.9±1.5 *1.3±0.1 
PRP 1 1 1 
PRP+Fibrinogen *2.2±0.6 *2.6±1.3 1.3±0.5 
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incubating human NPP spiked with fibrinogen or HBS with HSVEC, SMC, and TNFα-
HSVEC in the presence of tPA and monitored clotting and lysis by turbidity (Figures 3.8B-
D).  Compared to unstimulated HSVEC, SMC and TNFα-HSVEC significantly (p<0.05) 
shortened the time to peak turbidity of NPP clots (Figure 3.8E).  In contrast, elevated 
fibrinogen significantly (p<0.05) shortened the time to peak turbidity only on unstimulated 
HSVEC, but increased peak turbidity on all cell types.  We observed a similar pattern in 
mouse PPP spiked with human fibrinogen (Figure 3.8G).  These data indicate cellular PCA 
triggers fibrin formation, but fibrinogen concentration dictates fibrin incorporation into the 
clot and its resistance to lysis. 
 We then evaluated the effects of elevated fibrinogen on mechanical stability during tPA-
mediated lysis of human PRP and PPP clots.  Compared to control, addition of fibrinogen [to 
6 mg/mL, final (200%)] increased peak CEM, area under the lysis curve, and half lysis time 
(Figure 3.8H, Table 3.3).  Because fibrinogen produced similar effects in both PRP and PPP, 
these assays support findings that elevated fibrinogen promotes resistance of clots to 
fibrinolytic and mechanical disruption by a fibrin- (not platelet-) dependent mechanism. 
 
Elevated fibrinogen increases resistance to thrombolysis in vivo 
 Finally, because in vitro experiments suggested elevated fibrinogen increased clot 
stability, we assessed thrombolysis in vivo in mice with normal and elevated fibrinogen.  Due 
to the small size of the saphenous vein and its proximity to the saphenous artery, it was not 
feasible to continuously monitor blood flow during thrombolysis in the saphenous vein.  
Therefore, thrombolysis was only performed in the carotid artery model.  Following 
occlusive thrombus formation, we initiated lysis via bolus infusion of the tPA analog 
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TNKase.  TNKase’s increased fibrin specificity and enhanced resistance to inhibition by 
plasminogen activator inhibitor-1[33] provides a longer plasma half-life and facilitates 
dosing regimens (single IV bolus versus continuous infusion required for tPA/alteplase).  
Lysis of murine PPP clots was TNKase-dose-dependent (Figure 3.9A).  Importantly, human 
and murine fibrin are similarly cleaved by murine plasmin[34], and TNKase-mediated lysis 
was similarly dose-dependent with regard to fibrinogen [human (Figure 3.9B) or mouse 
(Figure 3.9C)] spiked into murine PPP.   
 TNKase infusion produced dose-dependent lysis of in vivo thrombi; 0.5, 2.5 and 5 mg/kg 
TNKase produced no (2/2 mice), partial (30-70% in 2/2 mice), or complete (5/5 mice) return 
of flow, respectively, in vehicle-infused mice within 1 hour of infusion (Figures 3.10A-F).  
Mice infused to 3.2±0.2 mg/mL final plasma fibrinogen (135%) showed only partial (0-30%) 
return of flow in 3/3 mice with subsequent re-occlusion following 5 mg/kg TNKase infusion 
(Figures 3.10G, H).  In contrast, mice infused to 4.0±0.1 mg/mL final plasma fibrinogen 
(170%) did not re-acquire flow for up to 120 minutes (3/3 mice), even at the highest TNKase 
dose or with repeat dosing (Figures 3.10I, J).  Together with in vitro lysis data (Figure 3.8), 
these in vivo data demonstrate hyperfibrinogenemia promotes resistance to thrombolysis. 
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Figure 3.9  Fibrinolysis of murine plasma clots is dose-dependent with regard to the 
TNKase and mouse or human fibrinogen concentrations.  A) Clotting was initiated with 
TF (1:30,000 Innovin) to recalcified murine PPP diluted 1:2 in the presence of 0 (open 
circles), 1 (closed circles), 2 (closed squares), 4 (closed diamonds), 8 (closed triangles), or 16 
(closed inverted triangles) µg/mL TNKase.  Clot formation and lysis were followed by 
turbidity.  Curves are from a single experiment representative of two independent 
experiments.  B, C) Recalcified murine PPP was spiked with human (B) or mouse (C) 
fibrinogen to achieve 2.4 (open circles), 3.4 (closed circles), 4.4 (closed squares), or 5.4 
(closed diamonds) mg/mL fibrinogen, final, diluted 1:2, and clotting was initiated with TF in 
the presence of 8 µg/mL TNKase and monitored by turbidity.  Polymerization curves were 
normalized to the starting turbidity from a single experiment representative of two 
independent experiments. 
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Figure 3.10  Hyperfibrinogenemia increases resistance to thrombolysis in vivo.  
Thrombosis was triggered in the carotid artery of wildtype mice infused with fibrinogen 
(plasminogen-, fibronectin-, vWF-, and factor XIII-depleted, concentrations indicated in the 
figure) or vehicle control.  Following stable occlusion for 5 minutes, mice were infused with 
TNKase (concentrations indicated in the figure).  Blood flow was monitored by flow probe 
throughout the experiment.  Shaded gray area represents the time of FeCl3 treatment plus 
time to reacquire flow information.  Each panel shows data from an individual mouse, 
representative of at least 2 mice for each condition.   
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3.5 Discussion 
 Although epidemiological studies have implicated elevated plasma fibrinogen as an 
independent risk factor for both arterial and venous thrombosis, it remains highly 
controversial whether fibrinogen is merely a biomarker of a coincident inflammatory state or 
is also a causative mechanism in the etiology.  We addressed this question in vivo by acutely 
elevating fibrinogen in mice and examining their susceptibility to thrombosis, and used ex 
vivo and in vitro experiments to elucidate biochemical and biophysical mechanisms by which 
fibrinogen contributes to thrombus formation and stability.  We also utilized a murine 
thrombolysis model to test thrombus stability in vivo.  Our findings show elevated fibrinogen 
levels:  1) specifically and independently shortened the TTO in both high (arterial) and lower 
(venous) shear injury models, 2) increased thrombus fibrin content, 3) promoted faster fibrin 
formation, higher network density, and increased clot strength and stability in TF-initiated in 
vitro models that recapitulate in vivo thrombosis, and 4) increased thrombus resistance to 
lysis in vivo.  Together, these findings show hyperfibrinogenemia independently promotes 
thrombosis, identify biochemical and biomechanical mechanisms by which elevated 
fibrinogen levels contribute to thrombus formation, and demonstrate a critical role for plasma 
fibrinogen levels in resistance to thrombolytic therapy. 
 Our study is the first to show elevated fibrinogen significantly and independently 
shortens the TTO after acute injury.  These findings differ somewhat from observations that 
transgenic hyperfibrinogenemic mice demonstrate a non-significant trend to shorter time to 
75% occlusion in a FeCl3-carotid model.[15]  Differences in the two studies include the 
method of elevating fibrinogen levels (infusion versus transgenic expression) and final 
fibrinogen levels (170% versus 145%[15]).  In our study, mice infused with lower fibrinogen 
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levels (to 135%) showed a TTO of 9 minutes (median) after carotid artery injury, which was 
not significantly different from control mice (data not shown).  Additionally, Kerlin et al.[15] 
utilized mice with elevated murine fibrinogen, whereas the mice in our study had a mixture 
of human and mouse fibrinogen.  Differences between these two molecules may make human 
fibrinogen more prothrombotic.  Finally, the higher FeCl3 concentrations (20%) used in the 
earlier study[15] may have dampened differences[35] between normal and 
hyperfibrinogenemic mice.  Our findings also differ somewhat from observations that human 
fibrinogen g’ chain expression in mice paradoxically decreases thrombus weight following 
electrolytic femoral injury.[17]  However, the total fibrinogen levels achieved in human g’-
expressing mice were lower than in controls, so any role of hyperfibrinogenemia was not 
examined in that study.  Our in vivo observations are supported by ex vivo and in vitro cell-
based experiments that recapitulate aspects of the murine thrombosis models.  Notably, these 
findings are consistent with studies demonstrating fibrin network density, mechanical 
stability, and resistance to lysis are positively correlated with fibrinogen concentration in 
clots triggered by exogenous thrombin[24, 30, 36, 37], but extend these findings to a more 
physiologically-relevant model in which clotting was initiated by TF-bearing primary cells.  
The vascular cells used in the current study model both arterial (atherosclerotic) disease 
where plaque rupture exposes blood to subendothelial cells (e.g. SMC) and venous disease 
where clots are thought to arise on intact but inflamed endothelium (e.g. TNFα-HSVEC).[19]  
To our knowledge, these experiments are the first to address the role of elevated fibrinogen in 
a cellular, TF-based system.  Together, these in vivo and in vitro observations link 
hyperfibrinogenemia to thrombotic disease and suggest specific mechanisms by which 
elevated fibrinogen is pathogenic.   
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  Our study correlating abnormal fibrin quality with thrombosis in hyperfibrinogenemia 
informs several patient cohort studies.  Of note, both hyperfibrinogenemia and denser, 
fibrinolysis-resistant clots were observed in plasma from patients with coronary artery 
disease, uniting observations of elevated fibrinogen, abnormal clot quality and cardiovascular 
disease in a single patient cohort.[36]  Abnormal fibrin network structure and/or function 
(high mechanical strength and/or increased resistance to lysis) have also been detected in 
plasma clots from patients with diabetes[38], ischemic stroke[39], pulmonary 
hypertension[40], myocardial infarction (MI)[36, 41], venous thromboembolism (VTE)[42, 
43], and healthy relatives of patients with premature coronary artery disease[44].  Overall, 
these studies suggest abnormal fibrin quality is a pathologic mechanism operant not only in 
hyperfibrinogenemia, but also in other prothrombotic pathologies. 
 A particularly interesting outcome of our study is the observation that 
hyperfibrinogenemia did not cause spontaneous thrombosis in vivo.  This observation is 
consistent with reports that injecting human fibrinogen into mice does not cause spontaneous 
fibrin deposition[26] and importantly, with findings that while hyperfibrinogenemia is a 
thrombosis risk factor[1-9], it does not cause thrombosis ipso facto.  Virchow proposed 
multiple “hits” from abnormalities in plasma composition, vascular cell function, and blood 
flow are required to trigger thrombosis.  This paradigm suggests an initiating trigger, likely 
exposure of cellular PCA during plaque rupture or vasculitis, is required to initiate thrombus 
formation.  Indeed, markers of vascular disruption including circulating leukocyte and 
endothelial-derived microparticles are elevated 1.3-fold in VTE patients.[45]  Consistent with 
this hypothesis, the prognostic importance of elevated fibrinogen levels appears to be 
independent of, and additive to, myocardial damage (troponin-T levels) in patients with 
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unstable CAD.[8]  To our knowledge, few diagnostic algorithms simultaneously consider 
markers of tissue damage and plasma hypercoagulability when assessing thrombosis risk.  Of 
note is one study[4] that examined independent and combined effects of elevated fibrinogen 
and homocysteine (a potential initiator of endothelial damage) on mortality of patients from a 
high-risk cardiology clinic; elevated levels of both homocysteine and fibrinogen contributed 
to an increased hazard ratio, consistent with our findings that endothelial dysfunction (TF 
expression) and hyperfibrinogenemia independently promoted thrombus formation.  Reduced 
blood flow (stasis), the third component of Virchow’s Triad, is thought to explain differences 
in arterial and venous thrombosis.  The shear rates between arteries and veins differ 
significantly; in humans large arteries like the carotid have wall shear rates of 300-800 s-1 
while venous shear rates are in the range of 20-200 s-1 (reviewed in [46]).  Interestingly, 
hyperfibrinogenemia has been correlated with both arterial and venous thrombosis, 
suggesting hyperfibrinogenemia contributes to thrombus formation independently of the 
shear rate.  We addressed the role of shear by applying the FeCl3 injury model to both high 
(artery) and lower (vein) shear vessels.  Thrombi from saphenous veins appeared more fibrin-
rich than thrombi from carotid arteries (Figure 3.3), consistent with observations that lower 
shear promotes fibrin deposition.[27]  Notably, however, hyperfibrinogenemic mice 
demonstrated shortened TTOs and increased fibrin content in thrombi in both high and lower 
shear vessels (Figures 3.2, 3.3).  These findings do not diminish a role for stasis in 
thrombosis, but rather suggest the contributions of shear are eclipsed in the setting of 
hyperfibrinogenemia and potentially other pathologies as well. 
Thrombolytic therapy has met limited success.  The GUSTO-I trial demonstrated 
complete coronary artery perfusion determines 30-day survival after MI; however, tPA 
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therapy achieved perfusion in only 54% of patients.[47]  Similarly, in acute stroke, proximal 
arterial patency following tPA infusion correlated with positive long-term outcome, but was 
achieved in only 27% of patients.[48]  Interestingly, although prior studies associated 
thrombus platelet content with decreased tPA efficacy[49], our study shows that within a 
given thrombosis model increased fibrin content also decreases thrombolytic efficacy.  This 
novel finding suggests the plasma fibrinogen level present during thrombus formation is an 
independent predictor not only of thrombotic risk, but also of the potential efficacy of 
thrombolysis.  Of note is the experiment in which we saw no return of flow in the occluded 
carotid artery in spite of two doses of TNKase (Figure 3.10J); post-mortem dissection 
revealed diffuse bleeding from microvasculature within the neck and abdominal cavity.  
Given the risk and devastating consequences of intracerebral hemorrhage with thrombolytic 
therapy, our data suggest screening patients for fibrinogen levels may inform risk/benefit 
analysis prior to initiating thrombolysis.  Confirming a role for fibrinogen level in 
thrombolysis will require a study of patients whom received thrombolytic therapy and for 
whom both the fibrinogen level and degree of reperfusion are known.  Our data provide 
strong justification for such an investigation. 
 This study has potential limitations.  First, we used human fibrinogen to increase 
circulating levels in the mouse.  However, published studies[17, 25, 26] as well as our data 
demonstrate human fibrinogen is stable in murine circulation and incorporated into murine 
clots.  Moreover, elevating either human or mouse fibrinogen in mouse plasma increased 
peak turbidity and prolonged tPA- or TNKase-mediated fibrinolysis similar to that seen with 
tPA- or TNKase-mediated lysis of human fibrinogen in human clots (Figures 3.8, 3.9).  
Second, the FeCl3 model may not fully recapitulate thrombosis/thromboembolism; it will be 
  99 
interesting to examine the effects of hyperfibrinogenemia in other models (stasis- or 
electrolytic-based) in future studies.  Finally, we evaluated the immediate effects of 
fibrinogen on thrombosis, however, elevated fibrinogen may have additional prothrombotic 
effects in vivo.  Previous studies[50] demonstrated fibrin induction of TF in human vascular 
EC, suggesting prolonged exposure of vasculature to hyperfibrinogenemia may feedback on 
additional cellular mechanisms. 
 In conclusion, our results show hyperfibrinogenemia independently promotes thrombus 
formation and stability via increased fibrin network density and resistance to dissolution.  
These findings establish hyperfibrinogenemia in the etiology of both arterial and venous 
thrombosis/thromboembolism, and suggest fibrin is a potential therapeutic target in the 
management of these pathologies.  Furthermore, our study establishes a model for future 
investigations of plasma hypercoagulability and vascular dysfunction; modulating plasma 
composition via intravenous procoagulant infusion will allow examination of the specific 
roles of additional plasma proteins in thrombosis and thrombolysis. 
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Chapter 4 
 
Extent of Vascular Injury Determines Contribution of Elevated Factor VIII to 
Thrombogenesis in Mice 
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4.1  Abstract 
Studies have correlated elevated plasma factor VIII (FVIII) with thrombosis; however, it is 
unclear whether elevated FVIII is a proinflammatory biomarker, causative agent, or both.  
We raised FVIII levels in mice and measured the time to vessel occlusion (TTO) following 
ferric chloride-induced injury.  Compared to control (saline-infused) mice, elevated FVIII 
had no effect after longer (3-minute) carotid artery injury, but shortened the TTO after 
shorter (2-minute) injury (p<0.008).  Following injury, circulating thrombin-antithrombin 
(TAT) complexes were lower after short versus long injury (p<0.04), suggesting short 
treatment produced less coagulation activation.  TAT levels in FVIII-infused mice were 
higher than controls after short, but not longer injury.  Accordingly, elevated FVIII had no 
effect on in vitro thrombin generation or platelet aggregation triggered by high TF, but 
increased thrombin generation rate and peak (2.4- and 1.5-fold, respectively), and accelerated 
platelet aggregation (up to 1.6-fold) when initiated by low TF.  Compared to control mice, 
elevated FVIII stabilized thrombi (fewer emboli) after short injury, but had no effect after 
longer injury.  TTO and emboli correlated with TATs.  These results demonstrate 
dependence of FVIII activity on extent of vascular injury.  We propose elevated plasma 
FVIII is an etiologic, prothrombotic agent following minimal but not extensive vascular 
damage.  
.
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4.2  Introduction 
Elevated factor VIII (FVIII) levels have been consistently and positively associated with 
primary and recurrent venous thromboembolism (VTE) [Odds Ratio (OR) 2.0 – 10.8].[1-8]  
For example, the Leiden Thrombophilia (LITE) Study[6] showed FVIII concentrations over 
1.5 U/mL (150%) led to an OR greater than 5, and Kyrle et al.[4] showed relative risk of 
VTE recurrence was 6.6 in patients with FVIII levels over 2.34 U/mL (234% of normal).  
FVIII concentrations over 2 U/mL (200%) have been associated with an OR of VTE 
recurrence as high as 10.8.[3] 
In contrast to VTE, the role of FVIII in arterial thrombosis is controversial.  Using broad 
definitions of coronary heart disease (CHD) encompassing atherosclerosis, angina, transient 
ischemic attack, acute and non-acute myocardial infarction (MI) and death, several studies 
have associated elevated FVIII with CHD and/or stroke, with OR ranging from 1.2 – 2.65.[9-
12]  However, associations between FVIII activity and CHD[13] or ischemic heart 
disease[12] were lost following multivariate adjustment for diabetes and von Willebrand 
factor (vWF) levels, respectively.  Importantly, since FVIII is increased in diseases that 
induce an acute phase response, including myocardial infarction[14], surgery[15], and 
sepsis[16], it is unclear whether FVIII’s association with either venous or arterial thrombosis 
simply reflects an ongoing prothrombotic inflammatory process, or is a direct, causative 
mechanism in the thrombosis etiology and therefore a therapeutic target, or both.   
 Studies examining the role of elevated FVIII in murine thrombosis models have also 
shown discord.  Mice infused with recombinant human FVIII to 250% of normal demonstrate 
FVIII accumulation in thrombi and significantly enhanced thrombus size after photochemical 
(Rose Bengal)-induced carotid injury.[17]  In addition, inhibiting FVIII activity with a 
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monoclonal antibody blocks thrombus formation in a murine inferior vena cava (IVC) 
stenosis model and in baboons implanted with arteriovenous shunts.[18, 19]  In contrast, 
elevated FVIII (20% murine FVIII plus 280% infused human FVIII) does not promote 
microvascular or vena cava occlusion in vWF-deficient mice.[20, 21]  Together, these studies 
suggest a role for FVIII in arterial and venous thrombosis, but that additional modifiers 
modulate its relative impact. 
 In the current study, we used murine models of thrombosis in the vein and artery to 
assess the role of elevated FVIII in thrombus formation and stability, and used ex vivo and in 
vitro methods to identify the operant biochemical mechanisms.  Elevated FVIII augmented 
thrombus formation and stability after mild, but not severe ferric chloride (FeCl3) injury.  
FVIII’s effects were manifest via its ability to increase thrombin generation and accelerate 
platelet aggregation initiated by low, but not high TF activity.  These results demonstrate 
dependence of plasma FVIII activity on the extent of vascular injury.  We propose elevated 
plasma FVIII is an etiologic, prothrombotic agent in situations where there is moderate, but 
not extensive, vascular damage. 
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4.3  Materials and Methods 
Proteins and materials 
 Dulbecco’s modified Eagle’s Medium with high glucose/2 mM L-glutamine, 0.05% 
trypsin/ethylenediamine tetraacetic acid, and phosphate-buffered saline (10 mM phosphate 
pH 7.1, 150 mM NaCl) were from Gibco (Grand Island, NY).  Human monoclonal purified 
FVIII (Hemofil M) was from Baxter (Deerfield, IL).  FVIII-deficient (Hemophilia A, <1% 
FVIII activity) platelet-poor plasma (PPP) was from HRF Inc (Raleigh, NC).  Kontact (aPTT 
reagent) was from Thermo Fisher Scientific (Waltham, MA).  Thrombin fluorogenic 
substrate (Z-Gly-Gly-Arg-AMC) and calibrator (α2-macroglobulin/thrombin) were from 
Diagnostica Stago (Parsippany, NJ).  Factor Xa chromogenic substrate (Pefachrome FXa) 
and Pefabloc FG (Glycine-Proline-Arginine-Proline) was from Pentapharm (Basel, 
Switzerland).  Thrombin receptor activation peptide (Serine-Phenylalanine-Leucine-Leucine-
Arginine-Asparagine, TRAP) was from Bachem (Torrance, CA).  Collagen was from 
Chrono-Log (Havertown, PA).  Innovin was from Siemens (Plainsfield, IN).  Mouse anti-
human tissue factor (TF) antibody (HTF-1) was a kind gift from Dr. Ronald Bach (University 
of Minnesota).  Non-immune mouse IgG antibody (MOPC-1), adenosine diphosphate (ADP), 
FeCl3 and bovine serum albumin (BSA) were from Sigma-Aldrich (Saint Louis, MO).  Goat 
anti-mouse and anti-rabbit peroxidase-conjugated antibodies were from Calbiochem (La 
Jolla, CA).  Monoclonal anti-fibrin antibody (59D8) was the generous gift of Drs. Marschall 
Runge [University of North Carolina (UNC) Department of Medicine] and Charles Esmon 
(Oklahoma College of Medicine).  Biotinylated secondary antibodies were from Vector 
Laboratories (Burlingame, CA).  Target Retrieval Solution was from Dako (Carpinteria, CA).  
Tenecteplase was the generous gift of Genentech (San Francisco, CA).  Corn trypsin 
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inhibitor and factor X were from Haematologic Technologies Inc (Essex Junction, VT).  
Contact-inhibited normal pooled plasma (NPP) was prepared from whole blood from 40 
healthy subjects (50% female, 68% non-Caucasian) in a protocol approved by the UNC 
Institutional Review Board, as previously described.[22]  
 
Murine Thrombosis and Thrombolysis Models 
 Procedures were approved by the UNC Institutional Animal Care and Use Committee.  
Mice (6-8 week old male C57BL/6, Charles River Laboratories, Raleigh, NC) were 
anesthetized with 1.5-2% isofluorane in 2% oxygen, and the left saphenous vein was exposed 
under a SZX12 dissecting microscope (Olympus, Tokyo, Japan) and catheterized as 
described.[22, 23]  FVIII or vehicle (saline or saline/BSA) was administered through the 
catheter on a per weight basis [blood volume (mL) is 7% of body weight (g)] less than 5 
minutes prior to injury.  Published studies demonstrate human FVIII binds murine vWF[17], 
has comparable cofactor activity as murine FVIII[17], promotes coagulation after tail 
clipping and vessel injury in hemophilic mice[17, 24-27], and is inactivated by murine 
activated protein C (Steve Pipe, personal communication).  In addition, previous studies and 
our findings (data not shown) show FVIII has sufficient half-life in murine circulation[28, 
29] for these experiments.  The endogenous FVIII concentration in mice (1 U/mL, 
100%)[30] was raised by infusing human FVIII to 285% (total murine plus human FVIII) of 
normal, consistent with levels associated with thrombosis in humans.[1-12]   
 The saphenous vein and carotid artery thrombosis models were performed as 
described.[22]  Briefly, the right saphenous vein was exposed, treated with 5% FeCl3 (0.31 M 
FeCl3 on 0.5x2 mm filter paper) for 3 minutes, and washed with warm saline.  Blood flow 
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was monitored auditorily by Doppler ultrasonic flow probe.  On separate mice, the right 
common carotid artery was exposed after midline cervical incision, dried, treated with 10% 
FeCl3 (0.62 M on 0.5x0.5 mm filter paper) for 3 or 2 minutes, and washed with warm saline.  
Following injury, blood flow was monitored via Doppler transonic flow probe.  In both 
models, the time to occlusion (TTO) was the time between FeCl3 administration and lack of 
flow for 60 consecutive seconds.  Experiments were stopped at 45 minutes if no occlusion 
occurred.  Embolization was defined as a rapid increase in blood flow of at least 0.2 mL/min 
in the 5 minutes after stable occlusion occurred.  Either 10 minutes after stable occlusion or 
after 45 minutes without stable occlusion, blood was drawn from the IVC and processed to 
platelet-poor plasma (PPP) by centrifugation at 5,000xg for 10 minutes. 
 Thrombolysis was assessed in mice subject to 3-minute FeCl3 carotid artery thrombosis 
as described.[22]  Briefly, after 5 consecutive minutes of blood flow below 0.1 mL/min, mice 
were infused with tenecteplase (5 mg/kg) through the saphenous vein catheter while 
continuously monitoring blood flow. 
 
FVIII Activity Assay 
 Factor VIII activity was measured in PPP from FVIII-infused mice not subject to 
thrombosis.  Five and 30 minutes after FVIII infusion, blood was drawn from the IVC and 
processed to PPP.  Murine PPP was mixed with human FVIII-deficient PPP (5% murine PPP 
and 95% FVIII-deficient PPP), and clotting was initiated with Kontact (40% total volume) 
and calcium (10 mM, final).  The clot formation rate was measured in a SpectraMax Plus 340 
plate reader (Molecular Devices, Silicon Valley, CA)[31] and compared to a standard curve 
created by mixing mouse PPP spiked with FVIII (to 150-300%) with FVIII-deficient plasma.  
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Five and 30 minutes after FVIII infusion, FVIII activity was 285% and 220%, respectively 
(endogenous murine FVIII plus infused human FVIII).  
 
Measurement of circulating thrombin-antithrombin (TAT) complexes 
 Citrated blood samples were drawn from the IVC of mice subject to the FeCl3 carotid 
artery thrombosis model 10 minutes after stable occlusion.  TAT levels were measured by 
ELISA (Enzygnost TAT micro ELISA, Siemens, Deerfield, IL)  
 
Cell culture 
 Primary human aortic smooth muscle cells (SMC, Lonza Walkersville, Walkersville, 
MD) were cultured as directed in 5% CO2 at 37°C, and used between passages 3-6 to reduce 
phenotypic drift. 
 
Phospholipid vesicles   
 Phosphatidylcholine (egg), phosphatidylethanolamine (soy), and phosphatidylserine 
(porcine brain) were from Avanti Polar Lipids (Alabaster, AL).  Large unilamellar vesicles 
(41% phosphatidylcholine/44% phosphatidylethanolamine/15% phosphatidylserine) were 
made by extrusion, as described.[32]  
 
TF Activity 
 TF activity was measured by chromogenic substrate cleavage on a SpectraMax Plus340 
plate reader in the presence and absence of inhibitory anti-TF antibody or isotype control (10 
µg/mL HTF-1 or MOPC-1, respectively), as described.[22, 33] 
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Thrombin generation 
 Thrombin generation was measured by calibrated automated thrombography using a 
Fluoroskan Ascent fluorometer (ThermoLabsystem) as described.[33]  Briefly, recalcified 
(16 mM, final), lipidated (100 µM, final) NPP was spiked with FVIII to 2, 3, or 4 U/mL 
(200%, 300%, and 400% of normal, respectively), final, and immediately added to washed 
SMC monolayers (67.7% plasma, final).  Thrombin generation parameters (lag time and 
peak) were calculated using Thrombinoscope software Version 3.0.0.29 (Thrombinoscope 
BV, Maastricht, Netherlands).  The thrombin generation rate was calculated by dividing peak 
height by the difference from time to peak and lag time.   
 
H&E Staining and Immunohistochemistry 
 Fixed tissues were dehydrated and paraffin-embedded, and consecutive, five-micron 
sections cut and mounted at the UNC Lineberger Comprehensive Cancer Center Animal 
Histopathology Core.  Hematoxylin and eosin (H&E) staining was used to visualize the 
thrombus.  Immunohistochemistry (IHC) for fibrin(ogen) was performed with monoclonal 
antibody 59D8, as described.[22]  Negative controls were stained simultaneously in the 
absence of primary antibody. 
 
Platelet Aggregation  
 Platelet aggregation was performed as described on a Chrono-Log Optical Aggregometer 
470 (Havertown, PA).[22]  Aggregation was triggered by TRAP (50 µg/mL, final), collagen 
(2 µg/mL, final), ADP (2.5 µM, final) or TF [1:30,000 (high TF) or 1:200,000 (low TF)].  
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For experiments triggered with TF, Pefabloc FG (5 mg/mL, final) was included to inhibit 
fibrin polymerization.  
 
Statistical Methods 
 For TTO, conditions were compared pairwise by a log-rank test due to censored 
observations at 45 minutes (no stable occlusion).  For TATs and embolization analysis, 
conditions were compared by Mann-Whitney tests to account for both unequal variance and 
non-normality of outcomes.  For in vitro thrombin generation assays, significant differences 
between groups were identified by a one-way analysis of variance (ANOVA) with 
homogeneity tests and residual plots to check statistical assumptions.  To analyze the effect 
of FVIII concentration on thrombin generation parameters (lag time, rate and peak height), a 
one-sided Dunnett’s post-hoc test using 1 U/mL FVIII (100% FVIII) as the index group (on 
SMC of varying confluency, as indicated) was used, with a controlled type-I error rate no 
larger than 0.05 in the multiple testing between experimental and index groups.  For platelet 
aggregation data, normalized lag times where ratios were calculated between 200%, 300%, 
and 400% to 100% FVIII were tested by a one-sided t-test with a null hypothesis no smaller 
than 1.  Bivariate correlation analyses between TTO, TAT, and number of emboli were 
presented in Pearson's coefficient (denoted as R) that indicates the degree of linear 
dependence.  Statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago IL).  
P-values less than 0.05 were considered significant 
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4.4  Results 
Elevated FVIII shortens the TTO in a saphenous vein thrombosis model. 
 FeCl3 application to the saphenous vein of control (saline-infused) mice for 3 minutes 
produced occlusive thrombi in 20.3 (6.0) minutes [median (range)].  Consistent with 
epidemiologic studies showing a significant (up to 10.8-fold) increased risk of VTE in 
patients with elevated FVIII[1-8], 285% FVIII significantly shortened the TTO [12.7 (2.8) 
minutes, median (range), p<0.001] in the saphenous vein.  Infusing non-specific protein 
(BSA, equivalent w/w) did not shorten the TTO versus control mice.  Additionally, the 
shortened TTO was not due to vWF in the FVIII preparation; Hemofil M contains only trace 
human vWF (0.083 µg vWF/U FVIII).[34]  These findings indicate FVIII’s effect was 
specific and confirm a direct, pathogenic contribution of elevated FVIII in a murine model of 
thrombosis in a vein.  
 
Elevated FVIII shortens the TTO following short (2-minute), but not longer (3-minute), 
FeCl3 treatment to the carotid artery. 
 In contrast to VTE, the role of FVIII in arterial thrombosis is unclear.  We therefore 
tested the ability of FVIII to accelerate arterial clotting following 3-minute FeCl3 application 
to the carotid artery.  Representative flow tracings are shown in Figure 4.1A, 1B.  Control 
mice developed occlusive thrombi in 8.1 minutes (median, Figure 4.1F).  Surprisingly, 
although mice with hypercoagulability due to elevated fibrinogen demonstrate significantly 
shortened TTO under these conditions[22], mice with elevated FVIII did not (7.1 minutes 
median, p=0.6, Figure 4.1F).   
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Figure 4.1  Elevated FVIII shortens the TTO after 2-minute, but not 3-minute FeCl3 
injury to the carotid artery.  C57Bl/6 mice were infused with saline or FVIII to 285% of 
normal.  Thrombosis was induced by 10% FeCl3 application to the carotid artery for the 
indicated time (3 or 2 minutes) and the TTO was determined by flow probe.  In vessels that 
did not occlude, the TTO was recorded as 45 minutes.  (A-E) Representative flow tracings 
following 3- (A-B) or 2- (C-E) minute FeCl3 application to control (saline-infused, A, C and 
D) and FVIII-infused (B, E) mice.  Gray shaded area represents time of vessel drying, FeCl3 
administration and vessel washing, during which flow could not be monitored.  Brackets 
indicate the time from FeCl3 placement to the time of vessel occlusion.  (F) Quantification of 
TTO data.  Each point represents a separate mouse.  Lines show median values to 
accommodate censored data at 45 minutes.  *p<0.05  
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 Given studies demonstrating differential sensitivity to intrinsic pathway components with 
extent of FeCl3 injury[35, 36], we then tested a second set of conditions in which FeCl3 was 
applied to the carotid artery for only 2 minutes. Representative flow tracings are shown in 
Figure 4.1C-E.  Compared to 3-minute FeCl3 injury, control mice took significantly 
(p<0.005) longer to form stable thrombi following 2-minute FeCl3 injury (13 minutes, 
median, Figure 4.1F).  Interestingly, unlike the 3-minute injury model, mice with elevated 
FVIII exhibited a significantly (p<0.005) shorter TTO than control mice in this 2-minute 
injury model (7.8 minutes, median, Figure 4.1F).  Infusing BSA did not shorten the TTO 
versus control mice (data not shown).  These data indicate elevated FVIII promotes arterial 
thrombosis following short, but not long, application of FeCl3. 
 
Elevated FVIII increases thrombin generation in vivo following short, but not longer, 
FeCl3 treatment.  
Our TTO data indicated duration of FeCl3 application influenced the impact of FVIII on 
thrombogenesis.  To characterize the effect of FeCl3 injury and FVIII on in vivo procoagulant 
activity (PCA, thrombin generation), we measured circulating TATs.  Uninjured mice had a 
TAT level of 17.4±2.26 ng/mL.  Control mice subject to either 3- or 2-minute FeCl3 
treatment had TAT levels of 195±108 or 66.2±63.1 ng/mL, respectively (Figure 4.2).  TAT 
levels in control mice were significantly (p<0.05) higher following 3-minute injury than 2-
minute injury, indicating 3-minute FeCl3 application causes higher PCA than 2-minute FeCl3 
application.  Compared to controls, elevated FVIII did not increase TAT levels in the 3-
minute injury model (222±85.2 ng/mL, p=0.5), but caused significantly higher TAT levels 
than controls after 2-minute (175±115 ng/mL, p<0.05) FeCl3 application (Figure 4.2).   
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Figure 4.2  Both time of FeCl3 injury and elevated FVIII influence TAT complex 
formation.  Citrated blood samples were collected via IVC puncture from mice subject to the 
FeCl3 carotid artery thrombosis model.  TAT levels were measured by ELISA.  Samples 
showing hemolysis were excluded.  Each point represents a separate mouse.  Lines show 
mean values.  *p<0.05 
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Across all mice, TAT levels correlated with TTO values (R=0.388, p=0.055), suggesting 
differences in TTO resulted from differential PCA at the site of injury. 
 
Elevated FVIII increases thrombin generation in an in vitro model of mild, but not 
more severe, vascular injury. 
Given findings associating TTO with circulating TAT levels, we hypothesized that the 
duration of FeCl3 application determined the extent of vascular injury, and consequently, the 
relative impact of extrinsic (TF-dependent) and intrinsic (FVIII-dependent) contributions to 
thrombin generation.  To specifically interrogate the relationship between vascular PCA and 
plasma FVIII levels on thrombin generation kinetics, we modeled vascular injury in vitro by 
culturing primary SMCs at 100, 60, and 20% confluency to model high, medium, and low 
levels of vascular damage, respectively.  Wang et al. previously showed SMC TF has a 
central role in FeCl3-induced vascular injury.[37]  SMC cultures at 100, 60, and 20% 
confluency expressed 5.5±0.74, 3.7±0.66, and 0.82±0.32 pM TF, respectively.  We first 
incubated re-calcified NPP [1 U/mL FVIII (100%)] with SMCs and measured thrombin 
generation (Figure 4.3).  Lipids (100 µM, final) were included to compensate for different 
lipid concentrations in cultures with different SMC plating densities.  Similar to thrombin 
generation triggered by 5 and 1 pM soluble TF[38], decreasing cell density (decreasing TF 
activity) significantly (p<0.05) prolonged the lag time and decreased the thrombin generation 
rate and peak height (Figure 4.3D-F).   
 We then determined the effect of FVIII on thrombin generation at each confluency level 
by incubating SMCs with recalcified, lipidated NPP spiked with FVIII [to 2 U/mL (200%), 3 
U/mL (300%) and 4 U/mL (400%), final], Figure 4.3).  Elevated FVIII non-significantly  
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Figure 4.3  FVIII increases thrombin generation in an in vitro model of mild, but not 
severe, TF (SMC) exposure.  Recalcified (16 mM, final) human NPP spiked with FVIII or 
HBS was added to SMC monolayers of varying densities.  Thrombin generation was 
measured by calibrated automated thrombography, as described.[22, 33]  (A-C) Thrombin 
generation curves representative of five independent experiments with SMC at 100% (A), 
60% (B), and 20% (C) confluency.  Symbols are: 100% (open circles), 200% (closed circles), 
300% (closed squares), and 400% (closed diamonds) FVIII, final.  (D-F) Mean values (± 
standard deviation) for (D) lag, (E) rate, and (F) peak height of thrombin generation for all 
five experiments with human NPP (1 U/mL FVIII) at different SMC confluency levels.  
*p<0.05 versus indicated group.  (G-I) Mean values (± standard deviation) for the (G) lag, 
(H) rate, and (I) peak height of thrombin generation for all five experiments, at varying FVIII 
levels.  *p<0.05 versus 1 U/mL within each confluency level. 
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shortened the lag time in reactions with SMCs at all confluencies  (Figure 4.3G); this effect 
was more pronounced at lower SMC confluencies.  At 100% confluency (high TF), FVIII 
had no effect on the rate or peak height (Figure 4.3H-I).  At 60% confluency (medium TF), 
400% FVIII increased the rate (p<0.05), but not peak height.  At 20% confluency (low TF), 
both 300% and 400% FVIII significantly (p<0.005) increased the rate and peak height 
(Figure 4.3H-I).  These results are consistent with our previous findings using lipidated TF; 
400% FVIII increases the peak height to a greater extent in reactions triggered by low (1 pM) 
than high (5 pM) lipidated TF (164% and 115% of normal, respectively).[38]  The 
significantly faster rate of thrombin generation in both low TF[38] and 20% SMC (Figure 
4.3H-I) was consistent with the shorter TTO in the 2-minute FeCl3 injury model in vivo. 
 Together, these in vivo and in vitro data show FeCl3-induced vascular damage induces 
PCA (thrombin generation).  Elevated FVIII augments thrombin generation and 
consequently, thrombus formation, following mild, but not more severe vascular injury. 
 
Elevated FVIII does not alter thrombus morphology or increase thrombus fibrin(ogen) 
content. 
 We previously showed hyperfibrinogenemic mice exhibit increased thrombus fibrin 
deposition.[22]  Since hyperfibrinogenemia promotes thrombosis by increasing thrombus 
fibrin(ogen) content[22] we tested whether elevated FVIII and its subsequent increase in 
thrombin generation in the 2-minute injury model similarly increased thrombus fibrin(ogen) 
content.  H&E staining showed similarly extensive, occlusive thrombi with similar vessel 
diameters, containing distinct regions of anucleate, proteinaceous material and erythrocytes 
in thrombi from control and FVIII-infused mice (Figure 4.4).  IHC of thrombi from both  
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Figure 4.4  Elevated FVIII does not increase fibrin(ogen) incorporation into thrombi 
following FeCl3 injury.  Representative sections through thrombi formed in the carotid 
artery after (A) 2-minute or (B) 3-minute FeCl3 application.  The dark region on the exterior 
of the vein is the site of FeCl3 application.  H&E staining shows regions of protein and 
packed erythrocytes.  Immunohistochemistry for fibrin (59D8) shows weak fibrin staining 
concentrated primarily at the luminal edge of proteinaceous regions.  “No 1°” indicates 
antibody 59D8 was omitted from the IHC as a negative control.  All images were taken at the 
same magnification (20X); the micron bar is 31 µm. 
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control and FVIII-infused mice demonstrated weak fibrin staining concentrated primarily at 
the luminal edge of proteinaceous regions.  There were no obvious differences in fibrin 
staining intensity between control and FVIII-infused mice (Figure 4.4), suggesting thrombus 
fibrin content was unchanged by elevated FVIII.  Together, these findings indicate FVIII did 
not shorten the TTO by increasing thrombus fibrin content. 
 
Elevated FVIII accelerates platelet aggregation when triggered with low, but not high, 
TF 
 To determine whether FVIII-dependent, elevated thrombin generation accelerated platelet 
incorporation into the thrombus, we raised FVIII levels in human PRP with additional human 
FVIII, and triggered platelet aggregation with TRAP, collagen, ADP, or TF.  Elevated FVIII 
had no effect on platelet aggregation initiated by TRAP, collagen, or ADP, showing that 
FVIII does not impact platelet function in the absence of thrombin generation (data not 
shown).  In reactions triggered by TF, FVIII had no effect on either the rate or maximum 
amplitude of platelet aggregation (Figure 4.5A).  Interestingly, whereas elevated FVIII had 
no effect on the lag time in reactions triggered with high TF, elevated FVIII dose-
dependently shortened the lag time of platelet aggregation in reactions triggered by low TF 
(p<0.05, Figure 4.5A-B).  These data are consistent with the FVIII-dependent shortening in 
TTO after 2-, but not 3-minute injury, and suggest elevated FVIII shortened the TTO by 
accelerating platelet activation/aggregation.  
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Figure 4.5  Elevated FVIII accelerates platelet aggregation when initiated with low, but 
not high TF. Platelet aggregation in human PRP spiked with human FVIII (final 
concentrations indicated) was triggered by re-calcification and addition of TF and monitored 
by turbidity as described in Methods and [22].  Graphs shown are from one experiment, 
representative of 4-6 experiments at each TF concentration.  (A) High TF (1:30,000 Innovin, 
final).  (B) Low TF (1:200,000 Innovin, final).  Note difference in x-axis (time) scaling in 
(A) and (B). (C-D) Quantification of lag time data initiated with high (C) and low (D) TF, 
respectively.  Graphs show mean ± standard error of the mean.  *p<0.05 versus 100% FVIII 
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Elevated FVIII increases thrombus stability following mild, but not severe, vascular 
injury. 
 Finally, since both shorter TTO and higher PCA have previously been associated with 
increased thrombus stability[22, 33, 39], we examined thrombus stability in the carotid artery 
of mice as functions of both duration of FeCl3 treatment and FVIII level.  Example tracings 
from experiments with control (saline-infused) mice after 3- and 2-minute injury are shown 
in Figure 4.6A and 4.6B, respectively.  Mice treated with FeCl3 for 3 minutes demonstrated 
stable occlusion (<0.1 mL/min blood flow for 5 consecutive minutes), whereas mice treated 
with FeCl3 for 2 minutes did not.  We quantified clot stability by counting the number of 
embolic events (rapid increase in blood flow of at least 0.2 mL/min) in the 5 minutes 
following the TTO.  Mice produced significantly (p<0.05) more emboli after 2-minute FeCl3 
injury than 3-minute injury (Figure 4.6C).  In the 2-minute injury model, FVIII-infused mice 
produced significantly (p<0.05) fewer emboli than control mice (Figure 4.6C).  However, 
there was no difference in number of emboli between control and FVIII-infused mice after 3-
minute injury (Figure 4.6C).  Across all mice, the number of emboli was significantly, 
positively-associated with TTO values (R=0.495, p=0.019) and significantly, negatively-
associated with TAT values (R=0.614, p=0.005). 
 Since control and FVIII-infused mice thrombosed with FeCl3 for 3 minutes demonstrated 
stable occlusion, we further examined thrombus stability by infusing these mice with the 
tissue plasminogen activator derivative, tenecteplase as described.[22]  Consistent with their 
similar TTO, TATs, and number of emboli, there was no difference in tenecteplase-induced 
thrombolysis; all mice showed complete return of blood flow (data not shown).  In total, 
these data suggest longer FeCl3 treatment (increased vascular injury) produces highly stable 
  127 
thrombi irrespective of intrinsic pathway components, whereas shorter treatment (less injury) 
produces unstable thrombi.  Elevated FVIII stabilizes thrombi after mild, but not severe 
vascular injury.   
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Figure 4.6  Both lengthier FeCl3 treatment and elevated FVIII increase thrombus 
stability.  C57Bl/6 mice were infused with saline or FVIII to 285% of normal.  Thrombosis 
was induced by 10% FeCl3 application to the carotid artery for the indicated time (3 or 2 
minutes).  Following stable occlusion, flow was monitored for 5 minutes to count embolic 
events (defined as a rapid increase in blood flow of at least 0.2 mL/min).  (A-B) 
Representative flow tracings following 3- (A) and 2-minute (B) FeCl3 application to control 
(saline-infused) mice, respectively.  Gray shaded area represents time of vessel drying, FeCl3 
administration and vessel washing, during which flow could not be monitored.  Brackets 
indicate the time from FeCl3 placement to the time of vessel occlusion.  Arrows show emboli 
(marked with E) in the 5 minutes after stable occlusion.  (C) Quantification of embolization 
data.  Each point represents a separate mouse.  Mice that did not achieve stable occlusion 
were excluded.  Lines show mean values.  *p<0.05 
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4.5 Discussion 
Epidemiologic studies have repeatedly correlated elevated plasma FVIII levels with VTE.  
However, the role of FVIII in arterial thrombosis is controversial.  In addition, for both 
venous and arterial thrombosis, it is unclear whether elevated FVIII is merely a 
proinflammatory biomarker[14-16], a causative mechanism in the disease etiology, or both.  
We acutely elevated FVIII in mice and examined their susceptibility to thrombosis, and used 
ex vivo and in vitro methods to elucidate biochemical mechanisms for the observed effects.  
Our findings confirm an etiologic, prothrombotic role for elevated FVIII in veins.  Moreover, 
our findings show elevated FVIII:  1) shortened the TTO after 2-, but not 3-minute FeCl3 
treatment to the carotid artery, 2) increased thrombin generation in mice after 2- but not 3-
minute FeCl3 treatment, 3) augmented the thrombin generation rate and peak in vitro with 
low, but not high, TF (SMC) exposure, 4) accelerated the onset of platelet aggregation 
initiated by low TF, and 5) promoted the formation of more stable thrombi (fewer emboli) 
following 2-, but not 3-minute injury in mice.  Together, these findings demonstrate an 
etiologic role for FVIII in thrombosis, but suggest dependence of plasma FVIII activity on 
the extent of vascular injury.  
 We and others have previously shown dose-dependent effects of TF activity on thrombin 
generation in vitro.[33, 38, 40]  Our data quantifying circulating TAT complexes in mice 
subject to 2- and 3-minute FeCl3 injuries extend the in vitro findings with soluble and cellular 
TF to the in vivo models and provide a rationale for the differences in TTO and thrombus 
stability.  Compared to shorter FeCl3 treatment, longer FeCl3 application produced higher 
circulating TAT levels, suggesting prolonged FeCl3 treatment produced a more severe injury 
with higher exposure of cellular procoagulant (TF) activity.  Our findings do not rule out the 
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possibility that longer FeCl3 treatment also increased platelet deposition by exposing more 
subendothelial collagen than the shorter injury.  However, we were able to recapitulate 
effects of longer and shorter FeCl3 treatment on thrombin generation and platelet aggregation 
by varying the soluble TF concentration ([38] and Figure 4.5), or SMC confluency in vitro 
(Figure 4.3), suggesting differential exposure of procoagulant (TF) activity differentiates 
these treatments.  Any effect on platelets of collagen exposure between the 2- and 3-minutes 
injury models would occur distinctly from, but potentially in addition to, effects of PCA.  
Importantly, our observation that TAT measurements correlate with thrombus formation 
(TTO) and stability measurements provides a means of quantifying differences in extent of 
vascular injury in different in vivo models.  This information may enable reconciliation of 
differences in outcome measures between studies using different thrombosis models. 
 Patients with elevated FVIII demonstrate elevated circulating prothrombin fragment 1.2 
and TAT complexes[5], and we and others have shown elevated FVIII increases thrombin 
generation in vitro[38, 41-43] and in vivo[43].  Interestingly, the in vitro studies show a 
stronger effect of elevated FVIII in reactions triggered with low TF than high TF.  It is 
therefore of considerable interest that elevated FVIII shortened the TTO and improved 
thrombus stability in the carotid artery following shorter, but not longer, FeCl3 application.  
Previous studies of intrinsic pathway components have demonstrated dose-dependent effects 
of FeCl3 treatment on thrombosis; mice lacking intrinsic pathway factors XI or IX develop 
occlusive thrombi in the carotid artery following high (10%), but not lower (3.5 or 5%) FeCl3 
treatment.[35, 36]  While previous studies hypothesized increased FeCl3 injury reduces 
sensitivity to intrinsic factors by increasing TF/VIIa activity[35, 36], our study is the first to 
show a mechanism for differences in mild and severe FeCl3 injury: differential PCA, 
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measured by TAT complex formation.  Indeed, the sensitivity of intrinsic pathway 
components is perhaps best demonstrated by differences in the prothrombin time (PT) and 
partial thromboplastin time (PTT) tests.  Whereas the PT detects clotting deficiencies due to 
extrinsic and common pathway components, its high TF concentrations mask effects of 
factors VIII or IX deficiency.  Lower TF concentrations in a PTT reveal FVIII or factor IX 
deficiencies.  To our knowledge, our study is the first to demonstrate an interaction between 
extent of vascular injury and effect of plasma hypercoagulability in vivo.  This interaction 
suggests more severe injury (longer application of FeCl3) exposes a sufficiently high amount 
of TF activity to negate effects of elevated FVIII.  In contrast, less severe injury (shorter 
application of FeCl3) exposes less TF activity, enabling a role for FVIII in PCA. 
 Our data demonstrating a etiologic role for FVIII in thrombosis are consistent with 
previous findings that elevated FVIII promotes Rose-Bengal-induced thrombosis[17], 
stabilizes thrombi (decreases microvascular thrombus embolization)[20], and normalizes the 
blood clotting time in vWF-deficient mice[20], and that FVIII inhibition blocks thrombus 
formation in murine and baboon thrombosis models[18, 19].  By comparing severe and mild 
vascular injuries, our study illuminates specific contributions of vascular procoagulant 
activity not apparent in the prior reports.  Our findings differ somewhat from observations 
that elevated FVIII (to 250%) increases thrombus size.[17]  In our study, thrombi in control 
and FVIII-infused mice appeared morphologically similar, with no obvious differences in 
thrombus size (vessel diameter), or final platelet or fibrin content.  Differences between these 
findings may reflect the injury model (FeCl3 versus Rose Bengal) and/or the method of 
quantification (IHC of fully-formed occlusive thrombi versus transillumination during 
thrombus formation which reflects the rate of thrombus growth).[17]  Although we were 
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unable to measure the rate of thrombus growth in vivo, our in vitro data indicate faster 
platelet activation/aggregation (Figure 4.5) and slightly faster fibrin polymerization (data not 
shown), consistent with their findings.  Brill et al. previously showed that elevated FVIII 
(300% of normal, 20% murine FVIII and 280% human FVIII) does not promote venous 
occlusion in vWF-deficient mice[20, 21], suggesting vWF is necessary for at least part of 
FVIII’s procoagulant effects.  Our study extends these findings by demonstrating a critical 
role for the extent of vascular injury in FVIII-dependent thrombin generation and 
thrombogenesis. 
 Besides elevated FVIII, epidemiologic studies have also correlated elevated fibrinogen 
levels (hyperfibrinogenemia) with thrombotic risk.[2, 8, 44]  We previously showed that like 
elevated FVIII, elevated fibrinogen shortens the TTO in both saphenous vein and carotid 
artery and increases thrombus stability.[22]  However, in contrast to elevated factor VIII, 
hyperfibrinogenemia shortens the TTO in the 3-minute FeCl3 carotid injury model.  
Moreover, elevated fibrinogen increases thrombus fibrin content[22], whereas elevated FVIII 
did not.  Rather, elevated FVIII accelerated platelet aggregation in a low TF/thrombin 
generation-dependent mechanism.  Since we and others have shown that high thrombin 
concentrations produce dense fibrin networks that are resistant to lysis[33, 39, 45], elevated 
FVIII may also alter the structure of fibrin present in the thrombi of mice treated with FeCl3 
for 2 minutes.  Unfortunately, while IHC provides quantitative information about fibrin 
content, which was not altered by elevated FVIII (Figure 4.4), it does not reveal information 
about fibrin network structure (individual fiber thickness or density).  Regardless, the 
differences between these findings demonstrate fundamental differences in the 
hypercoagulable mechanisms of elevated fibrinogen and elevated FVIII, and suggest 
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antithrombotic strategies could be tailored for a specific hypercoagulability (blocking 
thrombin generation/activity versus blocking fibrin formation).[46]   
 Our findings on the relationship between vascular injury and effect of FVIII on 
thrombosis inform epidemiologic studies showing either moderate or no relationship between 
FVIII and arterial thrombosis.[9, 10, 12, 13]  For example, using a broad definition of CHD 
that encompassed both mild and severe disease (definite, probable, or silent MI or definite 
CHD death), Folsom et al.[13] found little correlation between CHD and FVIII activity 
(OR=1.0).  Interestingly, plaque rupture is associated with exposure of high levels of TF 
(reviewed in [47]).  In contrast, using the presence of carotid plaque as a marker of mild or 
moderate disease, Pan et al.[9] showed a significant association between heart disease and 
FVIII (OR=2.65).  In light of our data, differences in the conclusions of these studies may 
reflect the severity of the study inclusion event; FVIII activity likely only contributes to 
thrombosis when there is mild or moderate TF exposure. 
 Given a causative role for FVIII in thrombosis, it is tempting to speculate about the 
potential efficacy of antithrombotic strategies that target FVIII activity in venous and arterial 
thrombosis.  Elevated FVIII is strongly (2- to 10.8-fold) associated with VTE, and partial 
inhibition of FVIII activity with a monoclonal antibody blocks thrombus formation in a 
murine IVC stenosis model and in baboons implanted with arteriovenous shunts.[18, 19]  In 
addition, patients with hemophilia A are protected from venous thrombosis.[48]  These data 
and our own findings in the saphenous vein thrombosis model suggest FVIII inhibition may 
protect against VTE.  However, hemophilia patients are only partially protected against 
ischemic heart disease[49] and epidemiologic studies inconsistently associate elevated FVIII 
with arterial thrombosis.  Together with our data, these observations suggest FVIII inhibition 
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would have only moderate efficacy in preventing arterial events triggered by high TF 
exposure.   
 This study has potential limitations.  First, we used human FVIII to increase circulating 
levels in the mouse.  However, our data and published studies demonstrate human FVIII is 
stable in murine circulation[28, 29], incorporated into murine clots[17] and supports clot 
formation in mice[17, 24-27].  Second, the FeCl3/saphenous vein injury model is not 
commonly used as a model of venous thrombosis; however, our findings are consistent with 
published data from other venous models and effectively demonstrate the pathological 
activity of elevated human FVIII to thrombi formed in murine veins.[17-19]  Finally, the 
FeCl3 thrombosis model also does not fully recapitulate atherosclerotic plaque rupture in 
humans; however, it exposes SMC TF and produces platelet-rich thrombi similar to those 
seen in arterial clots.[37, 47, 50] 
 In conclusion, our results show that both vascular damage and plasma hypercoagulability 
modulate thrombogenesis.  Following limited arterial injury, FVIII directly promotes 
thrombosis via increased thrombin generation resulting in accelerated platelet aggregation 
and increased thrombus stability.  Elevated FVIII does not promote thrombosis following 
severe vascular injury.  These findings provide a rationale for the controversy surrounding 
the role of FVIII in arterial thrombosis; FVIII’s prothrombotic effects in mice depend on the 
extent of injury that exposes procoagulant cells and triggers thrombin generation.  Although 
few diagnostic algorithms simultaneously consider markers of tissue damage and plasma 
hypercoagulability when assessing thrombosis risk, integrating these pieces of information 
may refine approaches to understand pathophysiologic mechanisms promoting thrombosis in 
humans.   
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Chapter 5 
 
Summary and Future Directions 
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5.1  Summary and future directions 
 Likely due to the ease of obtaining blood for ex vivo experiments, blood composition, 
including plasma coagulation factors, is generally well-studied.  As such, deficiencies in 
coagulation proteins such as factor VIII or IX (hemophilia A or B, respectively) are very 
well-characterized and easily diagnosed.  Interestingly, the role of elevated plasma 
coagulation factor levels (hypercoagulability) in the pathophysiology of thrombotic disorders 
is not well understood.  Therefore, this dissertation is focused on examining the role of 
hypercoagulability in coagulation both in vitro and in vivo.  The goal of this research was to 
determine whether elevated levels of specific coagulation factors contribute to risk of 
thrombosis. 
 In Chapter 2, we evaluated the effect of elevated factors XI, XI, VIII, V, X, prothrombin 
and fibrinogen on thrombin generation.  We used a thrombin generation assay (calibrated 
automated thrombography, CAT) which translated changes in individual factor levels to net 
changes in the resulting pattern of thrombin generation.  We were therefore able to 
demonstrate that increases in individual coagulation factors have an effect on the resultant 
thrombin generation profile.  Because thrombin generation determines the structure of the 
resulting fibrin clot, changes in thrombin generation may have a profound impact on the 
quality of the clot that is formed.  Specifically, high thrombin concentrations form dense 
fibrin clots with thin fibrin fibers that are resistant to lysis and therefore may be 
thrombogenic in vivo.[1-3]  These studies offer insight into how different coagulation factors 
modulate the rate of thrombin generation and may subsequently effect clot formation and 
stability. 
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 In Chapters 3 and 4, we looked more closely at elevated plasma fibrinogen 
(hyperfibrinogenemia) and FVIII.  The goal of these studies was to determine if elevated 
plasma fibrinogen and FVIII is causative in the etiology of arterial and/or venous thrombosis, 
and the mechanism by which these hypercoagulabilities exert their effects.  In both of these 
studies, we used an in vivo murine model in which the protein of interest (fibrinogen or 
FVIII) was infused into mice.  This model allowed us to specifically, acutely elevate only 
one coagulation factor to a precise level (corresponding to the levels seen in thrombotic 
disease in humans), and therefore determine its role in thrombosis after FeCl3 injury.  
Interestingly, hyperfibrinogenemia was prothrombotic (decreased the TTO) in both the 
(saphenous) vein and (carotid) artery.[4]  Hyperfibrinogenemia exerted this effect by 
increasing thrombus fibrin content, promoting faster fibrin formation, and increasing fibrin 
network density, strength, and stability.[4]  Importantly, hyperfibrinogenemia also increased 
resistance to pharmacologically-induced thrombolysis in vivo, demonstrating a direct, 
etiologic link between hyperfibrinogenemia, thrombosis, and thrombolysis in acute 
settings.[4]  
 Similarly, we acutely elevated FVIII in mice and examined their susceptibility to 
thrombosis, and used ex vivo and in vitro methods to elucidate biochemical mechanisms for 
the observed effects.  Our findings confirmed an etiologic, prothrombotic role for elevated 
FVIII in veins (shortened TTO in saphenous vein).  Interestingly, our findings in the carotid 
artery were in striking contrast to that of hyperfibrinogenemia; elevated FVIII shortened the 
TTO after 2-, but not 3-minute FeCl3 treatment to the carotid artery.  In addition elevated 
FVIII increased thrombin generation in mice after 2- but not 3-minute FeCl3 treatment, 
augmented the thrombin generation rate and peak in vitro with low, but not high, TF (SMC) 
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exposure, accelerated the onset of platelet aggregation initiated by low TF, and promoted the 
formation of more stable thrombi (fewer emboli) following 2-, but not 3-minute injury in 
mice.  Together, these findings demonstrate an etiologic role for FVIII in thrombosis, but 
suggest dependence of plasma FVIII activity on the extent of vascular injury. 
 Interestingly, both hyperfibrinogenemia and elevated FVIII are prothrombotic, but 
exerted their effects through different mechanisms; elevated fibrinogen increased thrombus 
fibrin content, density, strength and stability[4], whereas elevated FVIII accelerated platelet 
aggregation in a low TF/thrombin generation-dependent mechanism.  The differences 
between these findings demonstrate fundamental differences in the hypercoagulable 
mechanisms of elevated fibrinogen and elevated FVIII, and suggest antithrombotic strategies 
could be tailored for a specific hypercoagulability (blocking thrombin generation/activity 
versus blocking fibrin formation).[5] 
 We have created robust and effective in vivo and in vitro methodology for examining the 
role of specific hypercoagulabilities in thrombosis.  In the future, it will be interesting to use 
these methods to examine the role of elevated factors such as prothrombin.  It is known that 
elevated prothrombin levels, typically associated with the G20210A mutation, increase risk 
of venous thrombosis.[6]  In vitro with reconstituted systems and patient plasmas, 
hyperprothrombinemia increases the rate and peak of thrombin generation.[7-11]  The high 
thrombin generation rates promote formation of fibrin clots composed of a fine network of 
thin fibrin fibers[9] and increased activation of TAFI[12].  These data suggest a direct 
connection between elevated prothrombin, thrombin generation, and clot stability but the role 
of elevated prothrombin in thrombosis in vivo is yet to be determined.  Studies examining the 
role of prothrombin in a murine model of thrombosis are ongoing in our lab at this time. 
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